 
 Open, Single Arm, Prospective, Multicenter Study of  an 
Investigational Extended Wear Insulin Infusion Set During 
Home Use in People with Type 1 Diabetes 
Protocol Identifying Number: 150-1261-00 
IDE Sponsor: Capi[INVESTIGATOR_171637]: v.5.0 
08 February 2024 
CONFIDENTIAL  
  
	
			
 J AEB CENTER FOR HEALTH RESEARCH  D C O - 1 0 6 6 4  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 2 OF 59 Signature [CONTACT_171701], Single Arm, Prospective, Multicenter Study of  an 
Investigational Extended Wear Insulin Infusion Set During 
Home Use in People with Type 1 Diabetes 
Protocol Identifying Number: 150-1261-00 
IDE Sponsor: Capi[INVESTIGATOR_171637]: v.5.0 
 08 February 2024 
 
JCHR Protocol Director  
Name, degree John Lum, MS / Jaeb Center for Health Research 
Signature/Date  
 
Sponsor  Capi[INVESTIGATOR_171639], degree Alayne Lehman, RN, MS 
Signature/Date  
 
Clinical Lead Investigator  
Name, degree Rayhan Lal, M.D. / Stanford University 
Signature/Date  
 
Medical Monitor  
Name, degree Douglas B. Muchmore, M.D. / Capi[INVESTIGATOR_171640]/Date  
 John LumI agree to the terms defined by [CONTACT_171669]2024-04-10 09:49-04:00Alayne LehmanDigitally signed by [CONTACT_171670]: 2024.04.11 13:56:03 -07'00'
DOUGLAS MUCHMOREDigitally signed by [CONTACT_171671]: 2024.04.14 08:50:44 -07'00' 
	
			

JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 3 OF 59 KEY ROLES  
 
Protocol Chair/Director  
Name, degree Rayhan Lal, MD 
Institution Name [CONTACT_171702], degree John Lum, MS 
Institution Name [CONTACT_113488], degree Douglas B. Muchmore, MD 
Institution Name [CONTACT_171703][INVESTIGATOR_171641], degree Alayne Lehman, RN, MS 
Title Director Clinical Affairs 
Institution Name [CONTACT_171703][INVESTIGATOR_171642] 
 
  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-[ADDRESS_201241] 2021 Major revisi ons include: 
ï‚· Addressed FDA questions during IDE 
review 
ï‚· Revised language in primary efficacy 
endpoint  
ï‚· Revised inclusion criteria  
ï‚· Revised sample size 
ï‚· Revised statistical methods 
ï‚· Added background information 
ï‚· Added infusion set removal guidelines 3.0 Alayne Lehman Alayne Lehman 09 Jan 2023 Major r evisions include: 
ï‚· Addressed FDA questions during IDE 
review 
ï‚· Revised language in 
secondary/exploratory endpoints  
ï‚· Revised exclusion criteria 
ï‚· Added background information 
ï‚· Revised hyperglycemia management and infusion set guidelines 4.0* John Lum Alayne Lehman 05 Sep 2023 ï‚· Added version history table 
ï‚· Removed requirement to provide digital 
photographs of infusion sets/sites  
ï‚· Updated schedule of study visits and 
procedures in Table 1 
ï‚· Added background information in 
Chapter 1 
ï‚· Updated hyperglycemia management and 
infusion set guidelines language in 
Section 1.4 
ï‚· Removed insulin reimbursement per IRB 
request in Section 7.1 
ï‚· Revised key secondary endpoints in 
Sections 1.3.3 and 8.4.4 
ï‚· Fixed clerical errors, typos, formatting throughout protocol 5.0 Alayne Lehman, 
John Lum Alayne Lehman 08 Feb 2024 ï‚· Added Dexcom G7 CGM support to the 
protocol to allow participants to use 
either Dexcom G6 or Dexcom G7 in the 
study 
ï‚· Reworded â€œserum ketoneâ€ as â€œblood 
ketoneâ€ in eligibility criteria for 
consistency with â€œblood glucoseâ€ 
ï‚· Added clarification that insulin aspart 
and insulin lispro along with name [CONTACT_171704]. 
ï‚· Changed required time to be on baseline 
insulin from 3 months to 1 month 
ï‚· Clarified the screening assessment of 
Control-IQ adherence will be based on 
Subjectâ€™s personal t:connect data 
ï‚· Added wording to hyperglycemic/ketoic 
reportable event to include â€œthe participant contact[CONTACT_171672]  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 5 OF 59 VERSION NUMBER AUTHOR APPROVER EFFECTIVE 
DATE REVISION DESCRIPTION 
received guidance on how to manage the 
acute hyperglycemia/ketosis event unrelated to the infusion set  
   *Version in effect at study initiation 
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 6 OF 59 TABLE OF CONTENTS  
CHAPTER 1: BACKGROUND INFORMATION  .................................................. ........................................... [ADDRESS_201242] Hyperglycemia Management and Infusion S et Removal Guidelines ............................. ...... 22  
1.5 Potential Risks and Benefits of the Investigati onal Device System ................................ .................. 23  
1.5.1 Known Potential Risks ....................... ................................................... ...................................... 24  
[IP_ADDRESS] Risk of Hypoglycemia ...................... ................................................... ............................... 24  
[IP_ADDRESS] Risk of Hyperglycemia ..................... ................................................... ............................... 24  
[IP_ADDRESS] Insulin Infusion Risks .................... ................................................... .................................. 24  
[IP_ADDRESS] Risks of Use of Insulin Pump with Automated  Insulin Delivery ................................. ....... 24  
[IP_ADDRESS] Fingerstick Risks ......................... ................................................... ..................................... 24  
[IP_ADDRESS] CGM Subcutaneous Catheter Risks ........... ................................................... ...................... 25  
[IP_ADDRESS] Risks Associated with Device Reuse ........ ................................................... ....................... 25  
[IP_ADDRESS] Rapid-Acting Insulin Analog Adverse Reactio ns ................................................ ............... 25  
[IP_ADDRESS] Questionnaire-Associated Risks ............ ................................................... .......................... 25  
[IP_ADDRESS] Other Risks .............................. ................................................... ....................................... 25  
1.5.2 Known Potential Benefits .................... ................................................... ..................................... 25  
1.5.3 Risk Assessment ............................. ................................................... .......................................... 26  
1.6 General Considerations......................... ................................................... .......................................... 26  
CHAPTER 2: STUDY ENROLLMENT AND SCREENING  .................................................. ............................ [ADDRESS_201243] Exclusion Criteria .................... ................................................... .......................................... 28  
2.4 Eligibility Assessment and Baseline Data Collec tion .............................................. ......................... 29   
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 7 OF 59 2.5 Historical Information ........................ ................................................... ............................................ 29  
2.6 Screening Testing and Procedures .............. ................................................... .................................... 29  
2.7 Screen Failures ............................... ................................................... ................................................ 30  
CHAPTER 3: MAIN STUDY  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ................................................... .................... [ADDRESS_201244] Schedule .......... ................................................... ................................. 32  
3.5.1 Procedures at Study Visits .................. ................................................... ...................................... 33  
[IP_ADDRESS] Day 3 ..................................... ................................................... ........................................... 33  
[IP_ADDRESS] Week 2 .................................... ................................................... ......................................... 33  
[IP_ADDRESS] Week 6 .................................... ................................................... ......................................... 33  
[IP_ADDRESS] Final Visit................................ ................................................... ......................................... 33  
3.5.2 Study Completion ............................ ................................................... ......................................... 34  
3.5.3 Early Study Discontinuation ................. ................................................... .................................... 34  
CHAPTER 4: STUDY DEVICES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ................................................... ............... 35  
4.1 Description of the Investigational Device: Stea diSet Infusion Set ................................ .................... [ADDRESS_201245] Access to Study Devices at Study Closur e ................................................. .......................... 36  
CHAPTER 5: TESTING PROCEDURES AND QUESTIONNAIRES  .................................................. ............... 37  
5.1 Laboratory Testing ............................ ................................................... ............................................. 37  
5.1.1 HbA1c ....................................... ................................................... ............................................... 37  
5.1.2 Urine Pregnancy ............................. ................................................... .......................................... 37  
5.2 Questionnaires ................................ ................................................... ................................................ 37  
5.2.1 Screening Visit ............................. ................................................... ............................................ 37  
5.2.2 Week 2 Visit ................................ ................................................... ............................................. 37  
5.2.3 Final Visit ................................. ................................................... ................................................ 37   
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 8 OF 59 CHAPTER 6: UNANTICIPATED PROBLEM , ADVERSE EVENT , AND DEVICE ISSUE REPORTING  ............ 38  
6.1 Unanticipated Problems ........................ ................................................... .......................................... 38  
6.2 Adverse Events ................................ ................................................... ............................................... 38  
6.2.1 Definitions ................................. ................................................... ............................................... 38  
6.2.2 Reportable Adverse Events ................... ................................................... ................................... 39  
6.2.3 Hypoglycemic Events ......................... ................................................... ...................................... 40  
6.2.4 Hyperglycemic/Ketotic Events ................ ................................................... ................................. [ADDRESS_201246] igational Device .................................. ............... 41  
6.2.6 Severity (Intensity) of Adverse Events ...... ................................................... ............................... [ADDRESS_201247] Discontinuation of Study Device ..... ................................................... ............................ 44  
6.6.2 Criteria for Suspending or Stoppi[INVESTIGATOR_171643] S tudy .............................................. ....................... 45  
CHAPTER 7: MISCELLANEOUS CONSIDERATIONS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ................................. [ADDRESS_201248] Withdrawal ............................ ................................................... ............................................ 46  
7.7 Confidentiality ............................... ................................................... ................................................. 4 7 
CHAPTER 8: STATISTICAL CONSIDERATIONS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ........................................ 48  
8.1 Statistical and Analytical Plans .............. ................................................... ........................................ 48  
8.2 Statistical Hypotheses ........................ ................................................... ............................................. 48  
8.3 Power ......................................... ................................................... ................................................... .. 48 
8.4 Outcome Measures .............................. ................................................... ........................................... 48  
8.4.1 Clinical Events Committee ................... ................................................... .................................... 48  
8.4.2 Primary Efficacy Endpoint ................... ................................................... .................................... 48  
8.4.3 Safety Endpoints ............................ ................................................... ........................................... 49  
8.4.4 Key Secondary Endpoint ...................... ................................................... .................................... 49  
8.4.5 Other Secondary Endpoints ................... ................................................... ................................... 49   
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 9 OF 59 8.4.6 Exploratory Endpoint ........................ ................................................... ....................................... 49  
8.5 Analysis Datasets and Sensitivity Analyses .... ................................................... ............................... 50  
8.6 Analysis of the Primary Efficacy Endpoint(s) .. ................................................... .............................. 50  
8.7 Analysis of the Secondary and Exploratory Endpo ints .............................................. ....................... 50  
8.8 Safety Analyses ............................... ................................................... ............................................... 51  
8.9 Baseline Descriptive Statistics ............... ................................................... ......................................... 51  
8.10 Planned Interim Analyses ..................... ................................................... ........................................ 51  
8.11 Multiple Comparison/Multiplicity ............. ................................................... ................................... 51  
CHAPTER 9: DATA COLLECTION AND MONITORING  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ............................ 52  
9.1 Case Report Forms and Other Data Collection ... ................................................... ........................... 52  
9.2 Study Records Retention ....................... ................................................... ......................................... 52  
9.3 Quality Assurance and Monitoring .............. ................................................... ................................... 52  
9.4 Protocol Deviations ........................... ................................................... ............................................. 53  
CHAPTER 10: ETHICS /PROTECTION OF HUMAN SUBJECTS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .................. [ADDRESS_201249] Future Use of Stored Specimens and D ata ............................................... .................... 55  
CHAPTER 11: REFERENCES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ................................................... .................. 56  
APPENDIX A: RELEVANT LITERATURE ON INFUSION SETS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .................. [ADDRESS_201250] of Wear Time on PK/PD and Test Meal Resp onse .............................................. .................. 58  
A.3 Experience with Extended Wear (>3 days) ....... ................................................... ............................ 59  
 
 
  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-[ADDRESS_201251]  Diabetes Control and Complications Trial  
DKA Diabetic Ketoacidosis  
DOI Day of Insertion 
DPP-4 Dipeptidyl peptidase-4 
e.g. exempli gratia (for example) 
eCRF electronic Case Report Form 
et al. et alia (and others)  
etc. et cetera (and so forth) 
FDA Food and Drug Administration 
FL [LOCATION_012]  
GEE Generalized Estimated Equations 
GLP-[ADDRESS_201252] (that is) 
ICF Informed Consent Form 
ICH International Conference of Harmonization 
IFU Instructions For Use  
ID Identification 
IIS Insulin Infusion Set 
Inc Incorporated  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-[ADDRESS_201253] 
JCHR Jaeb Center Health Research  
JDRF Juvenile Diabetes Research Foundation 
MedDRA Medical Dictionary for Regulatory Activities 
mg/dL milligrams per deciliter 
Micro-CT micro computed tomography 
mmol/L millimoles per liter 
MRI Magnetic Resonance Imaging 
NGSP National Glycohemoglobin Standardization Progr am 
p probability 
PD  Pharmacodynamic 
pH power of Hydrogen 
PI [INVESTIGATOR_171644]-[ADDRESS_201254] 
WOCBP Women of Childbearing Potential  
 
  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 12 OF 59 SITE PRINCIPAL INVESTIGATOR [INVESTIGATOR_113411]: Open, Single Arm, Prospective, Mult icenter Study of an Investigational Extended Wear 
Insulin Infusion Set During Home Use in People with  Type 1 Diabetes 
Protocol Version/Date: v5.0 / [ADDRESS_201255] read the protocol specified above. In my for mal capacity as a Site Principal Investigator, my 
duties include ensuring the safety of the study sub jects enrolled under my supervision and providing t he 
Jaeb Center for Health Research, which serves as th e Coordinating Center for the protocol, with comple te 
and timely information, as outlined in the protocol . It is understood that all information pertaining to the 
study will be held strictly confidential and that t his confidentiality requirement applies to all stud y staff 
at this site. 
This trial will be carried out in accordance with I CH E6 Good Clinical Practice (GCP) and as required 
by [CONTACT_716]: [LOCATION_002] (US) Code of Federa l Regulations (CFR) applicable to clinical studies (45 
CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR  Part 312, and/or 21 CFR Part 812). 
As the Principal Investigator, I will assure that n o deviation from, or changes to the protocol will t ake 
place without prior agreement from the sponsor and documented approval from the Institutional Review 
Board (IRB), or other approved Ethics Committee, ex cept where necessary to eliminate an immediate 
hazard(s) to the trial subjects. 
All key personnel (all individuals responsible for the design and conduct of this trial) have complete d 
Human Subjects Protection Training and Good Clinica l Practice Training. Further, I agree to ensure tha t 
all staff members involved in the conduct of this s tudy are informed about their obligations in meetin g the 
above commitments. 
Investigatorâ€™s Signature __________________________ ________ Date _____ / _____ / _____ 
 dd mmm yyyy 
Investigatorâ€™s Name _______________________________ _____ 
Site Name/Number __________________________________ ___ 
  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 13 OF 59 PROTOCOL SUMMARY  
 
Title Open, Single-Arm, Prospective, Multicenter Study of  an Investigational Extended Wear 
Insulin Infusion Set During Home Use in People with  Type 1 Diabetes 
PrÃ©cis Prospective evaluation of the SteadiSet insulin inf usion set with 12 wear periods of up to 
7 days each in adults with type 1 diabetes (T1D) us ing Tandem pump with t:slim X2 
Control-IQ 
Investigational Device SteadiSet 
Objectives Primary Objective: 
ï€ The evaluation of SteadiSet device function as evid enced by [CONTACT_171673] w ithout ketosis 
Secondary Objectives: 
ï€ Characterization of safety endpoints, glycemic cont rol and insulin dosing while using 
the SteadiSet device 
Study Design Prospective, Multi Center, Single Arm study 
Number of Sites Up to 20 sites in the [LOCATION_002] 
Endpoint  Primary Efficacy Endpoint: 
Percentage of successfully inserted SteadiSet infus ion sets (i.e., not removed within 8 hours 
of insertion) that are not withdrawn from use prior  to 7 days (168 hours) due to either  
(1), (2), or (3): 
1. Blood Glucose value â‰¥250 mg/dL with ketones >1.0 mm ol/L, in the absence of 
illness or other physiological stress.  
2. Blood Glucose value â‰¥250 mg/dL for at least [ADDRESS_201256] 50 mg/dL. 
3. Investigator advises the infusion set should be rep laced to assure subjectâ€™s safety 
See Section 1.[ADDRESS_201257] Hyperglycemia Management an d Infusion Set Removal Guidelines 
for additional details. 
A Clinical Events Committee (CEC) will adjudicate p rimary and secondary clinical endpoint 
events based on review of all available information  that is relevant to determine whether 
protocol-defined endpoint events have occurred duri ng the study. See Section 8.4.1 Clinical 
Events Committee for additional details. 
Safety Endpoints: 
The incidence, severity, and relationship to the in vestigational device of all reported adverse 
events (serious and non-serious including diabetic ketoacidosis (DKA) and severe 
hypoglycemia) from day of insertion through day of device removal for each wear period. 
Key Secondary Endpoint: 
Proportion (%) of SteadiSet infusion sets withdrawn  from use at any time following insertion 
prior to 7 days (168 hours) as evidenced by [CONTACT_171674]. NOTE: infusion set removals prior to 168 hou rs due to miscalculation of date and/or 
time, along with other removals that cannot be ascr ibed to the investigational device 
performance, are excluded from this proportion calc ulation.  
1. Infusion set failure as defined in the Primary Endp oint (including any such 
removals occurring during the first 8 hours followi ng set insertion) 
2. Evidence of infusion set site infection defined as requiring treatment or at the 
investigatorâ€™s judgment  
3. Cannula dislodgement from subcutaneous (SC) space ( with or without liquid 
leakage at the cannula insertion site) 
a. Leakage at the cannula insertion site may or may no t be deemed by [CONTACT_171675]  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 14 OF 59  
b. Accidental removal events (e.g., tubing caught on d oorknob) are 
excluded from this proportion calculation 
4. Occurrence of a non-resolvable pump occlusion alarm  
5. Other device malfunction (e.g., inability to pi[INVESTIGATOR_171645], bending, or other 
malformation that might impact insulin infusion, se curement failure)  
6. Presence of pain of sufficient severity to prompt e arly removal of infusion set 
7. Any other event that can be ascribed to the investi gational device performance that 
results in failure of insulin delivery 
Other Secondary Endpoints: 
1. Standard glucose control metrics obtained from CGM,  including hyper- and 
hypoglycemic epi[INVESTIGATOR_1841], time in range, mean 24-hour glucose, and other measures 
2. Total daily insulin dose, basal dose, bolus dose , and bolus basal ratio overall and 
 b y  d a y  o f  i n f u s i o n  s e t  w e a r  
3. Subject tolerability levels for the infusion set in sertion as assessed by a pain scale 
of 0 to 100 with zero being no pain and 100 being s ignificant pain 
4. Hyperglycemia trends in days 1-3 versus after day 3   
5. Infusion set performance (including set failures as  defined above and also glucose 
metrics, insulin doses, pump occlusion alarms and h yperglycemia trends) in 
subjects who use low doses (e.g., <25 units/day) of  insulin and in subjects who 
experience frequent stops and start of pump use 
Exploratory Endpoint: 
1. HbA1c change from baseline to the end of study part icipation. 
Eligibility Criteria Inclusion Criteria:  
1. Age [ADDRESS_201258] 3 months of current 
experience with a Tandem pump 
6. Using Tandem t:slim X2 insulin pump with Control-IQ  technology for a minimum of 
[ADDRESS_201259]  85% of time with Control-IQ 
technology active 
8. HbA1c <9.0% in the last 6 months.  
9. Willing to implement and adhere to pump alert/alarm  settings on a study-provided 
pump as instructed during the study 
10. Willing to wear each investigational infusion set f or up to 7 days during each of the 12 
consecutive wear periods in the study 
11. Willing to perform blood ketone and blood glucose ( fingerstick) measurements as 
directed using provided ketone and blood glucose me ters and strips 
12. Access to internet for required periodic uploads of  study device data 
13. BMI in the range 18â€“35 kg/m2, both inclusive 
14. Currently using one of the following insulins with no expectation of a need to change 
insulin type during the study: 
a. Humalogâ„¢ (insulin lispro) 
b. NovoLogâ„¢ (insulin aspart) 
15. Using Humalogâ„¢ insulin lispro or NovoLogâ„¢ insulin a spart for a minimum of 1 
month at the time of enrollment  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 15 OF 59  
16. Willing to change insulin cartridge every 48-72 hou rs, as recommended by [CONTACT_4676]â€™s 
healthcare provider during the study 
17. Has routine access to a smart phone e.g., ability t o receive text messages  
18. Has the ability to understand and comply with proto col procedures and to provide 
informed consent (i.e., English proficient in both verbal and written communication) 
 Exclusion Criteria: 
1. Concurrent use of any non-insulin glucose-lowering agent, other than metformin 
(for example, GLP-1 agonists, Symlin, DPP-4 inhibit ors, SGLT-2 inhibitors, 
sulfonylureas) 
2. Female subject is pregnant, planning to become preg nant, or not using adequate method 
of contraception 
3. Epi[INVESTIGATOR_171646] 6 month s resulting in: 
a. Medical Assistance (i.e., paramedics, hospi[INVESTIGATOR_171647]) 
b. Loss of consciousness 
c. Seizures 
4. One or more epi[INVESTIGATOR_171648] (DKA)  in the last 6 months requiring 
hospi[INVESTIGATOR_059] 
5. Currently on a ketogenic or low-carbohydrate diet o f less than 60 grams of 
carbohydrates per day, or intending to begin one du ring the study period  
6. Known cardiovascular disease considered to be clini cally relevant by [CONTACT_093] 
7. Known history of any of the following conditions: 
a. Cushingâ€™s Disease 
b. Pancreatic islet cell tumor 
c. Insulinoma 
d. Lipodystrophy 
e. Extensive lipohypertrophy, as assessed by [CONTACT_8647] 
8. Currently undergoing treatment with: 
a. Systemic oral or intravenous corticosteroids (curre nt or within the last 8 weeks from 
screening), 
b. Thyroid hormones, unless use has been stable during  the past 3 months 
9. Significant history of any of the following, that i n the opi[INVESTIGATOR_171649] : 
a. Alcoholism 
b. Drug abuse 
10. Significant acute or chronic illness, that in the o pi[INVESTIGATOR_171650]  
11. Current participation in another clinical drug or d evice study 
12. Immediate family member (spouse, biological or lega l guardian, child, sibling, parent) 
who is a study site personnel directly affiliated w ith this study or who is an employee of 
Capi[INVESTIGATOR_171651] 300 with the goal of completing approximately  120 Subjects for each insulin type 
(Humalog and Novolog) 
Treatment Groups All subjects use the SteadiSet insulin infusion set  for [ADDRESS_201260] to complete the stu dy 
Study Duration (planned) [ADDRESS_201261] v isit  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 16 OF 59  
Protocol Overview/Synopsis Subjects with T1D and experience using a Tandem t:s lim X2 pump with Control-IQ 
technology will be evaluated for study participatio n. Following screening, eligible subjects 
will enter the active phase of the study and receiv e the SteadiSet infusion set and a 
study-provided Control-IQ pump for use during the s tudy. Subjects will wear the SteadiSet 
infusion set with the study pump for up to 7 days f or each of 12 consecutive wear periods. 
Statistical Methods and 
Sample Size Documentation Kaplan-Meier estimates will be reported along with a curve used to estimate the proportion 
of infusion sets that meet the primary and secondar y endpoint definitions. A point estimate 
and two-sided 95% confidence interval for the 7-day  survival rate will be calculated with a 
bootstrap to account for the correlated data from h aving each subject wear multiple infusion 
sets. A corresponding p-value will be given for the  null hypothesis that the true survival 
probability is 75%. 
If the true success probability is 83% and we conse rvatively estimate the within-subject 
correlation to be as high as 0.4, then a sample siz e of [ADDRESS_201262] would give 87% power  for a two-sided test at alpha = 0.[ADDRESS_201263] the null hypothesis that the success rate is  75%. Nine wears per subject, N=120 
subjects would give 86% power. 
  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 17 OF 59 SCHEMATIC OF STUDY DESIGN  
 
Figure 1. Study Schematic. Note timing of study visits/calls at [ADDRESS_201264] to initiation of Set #1 a nd likely will not correspond exactly 
with removal of Set #2 and Set #6, respectively. Se e Section 3.[ADDRESS_201265] sche dule details.  
 
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 18 OF 59 Table 1-1. Schedule of Study Visits and Procedures 
 Screening/ 
Baseline 
Visit Day 0 - 
Initiation of 
Study Infusion 
Set 3 Days 2 Weeks 6 Weeks Final Visit Unsched. 
Call/Visit 
Visit Window  N/A â‰¤14 days (-1 to +3 
days) (Â± 4 days) (Â± 7 days) (+ 7 days 
from final 
wear period) N/A 
Informed Consent (enrollment) X       
Eligibility Criteria  X1      
Medical History including baseline 
medications X       
Survey Usability, Satisfaction & Preference2  X  X  X  
Height and Weight to Calculate BMI X       
Pregnancy Test (Urine) for WOCBP3  X      
Central Lab HbA1c  X    X  
Subject Training for SteadiSet  X      
Upload Ketone and Glucose Meters    X X X  
Insertion of 1st SteadiSet by [CONTACT_27720]  X      
Pain Assessment   Infusion Set Insertion  
Dispense SteadiSets & other study supplies X      
Upload Insulin Pump Data X  At time of each infusion set removal and study visi t X 
Adverse Event Assessment   X X X X X X 
Reportable Medication Changes   X X X X X 
Collect all used & unused infusion sets      X  
1Confirm eligibility if the screening and initiation  visits are not completed on the same day. 
2There are [ADDRESS_201266]â€™s opi[INVESTIGATOR_171652] t and should be completed before insertion of the s tudy device. The next two are 
surveys assess the Subjectâ€™s opi[INVESTIGATOR_23748] d evice after use. Site to send the appropriate link to Subject to complete each assessment. 
3Pregnancy test should be completed at Day [ADDRESS_201267].  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 19 OF 59 Chapter 1:  Background Information 1 
1.1 Introduction 2 
Type 1 diabetes (T1D) causes autoimmune pancreatic beta cell destruction and lifelong dependency on 3 
exogenous insulin, typi[INVESTIGATOR_171653] m ultiple daily injections or via an infusion set wit h a 4 
subcutaneous catheter (continuous subcutaneous insu lin infusion, or CSII). [ADDRESS_201268] inf usion 7 
set failures are due to cannula kinking or a clogge d insulin port3, Table 1-1. Additional literature on 8 
infusion set failures, which is indicative of a hig h failure rate with currently available infusion se ts, is 9 
provided in Appendix A, Relevant Literature on Infu sion Sets. 10 
Table 1-1. Infusion Set Failure Rate by [CONTACT_171676] 11 
DAY(S) OF USE FAILURE RATE 
Day 1 > 15% 
Day 3 > 25% 
Day 7 > 65% 
 12 
This high failure rate prevents wider adoption of i nsulin pump therapy that could improve current pati ent 13 
outcomes and expand pump access to more users. 14 
Results from pre-clinical animal and bench studies of the Capi[INVESTIGATOR_171654] 15 
(see Section 1.1.2) have shown a lower rate of cann ula kinking (2.1% vs 32.5% for straight Teflon 16 
cannulas, p<0.001) and improved infusion set functi onality for extended use periods beyond 72 hours 17 
(In-Vivo Study of the Tissue Trauma Caused by a New , Kink-Resistant Insulin Infusion Set Compared 18 
to a Commercial Control over Two Weeks of Wear Time  [unpublished data, 2021]). 19 
Currently, a change of insulin infusion sets is rec ommended every 72 hours for commercially available 20 
Teflon insulin infusion sets and every 48 hours for  steel cannulas.1,7 Based on clinical experience and 21 
recently published data, there is evidence that can nula wear time might be extended in some patients 22 
without worsening of glucose control. 1,3,8,9 Other patients report a worsening of glycemic cont rol over 23 
time, which prompts them to change the infusion set  prior to the recommended 3-day period.1,3 An ideal 24 
IIS would provide high reliability while leveraging  the on/off insulin pharmacokinetics (PK) and 25 
pharmacodynamics (PD) of modern rapid-acting insuli n analogs over an extended period (>3 days). 26 
An optimized IIS would also enhance the safety and performance of a closed-loop artificial pancreas 27 
(AP) system,10 perhaps with CGM and insulin infusion combined in one device, capable of a 7+ day 28 
wear-time.11-13 29 
1.1.2  Preclinical Testing of the Capi[INVESTIGATOR_171655] 30 
Between 2016 and 2018, Capi[INVESTIGATOR_171642], Inc. ( CapBio) and the Jefferson Artificial Pancreas 31 
Center (JAPC, Thomas Jefferson University, Philadel phia, PA) performed preclinical studies in 18 swine  32 
funded by [CONTACT_171677]. The JAPC research team iteratively tested multiple generations of cannulas developed 33 
by [CONTACT_171678] . 34 
The Achilles prototype was well tolerated by [CONTACT_171679] (n=3) with no signs of inflammation or infect ion. 35 
The JAPC was able to show the improved CapBio cannu la design successfully prevented kinking (0% 36 
versus 57% kink rate in Silhouette commercial angle d cannulas, p<0.001). As measured in micro-CT, 37  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 20 OF 59 the surface-area-to-volume ratio of a bolus of insu lin/x-ray contrast agent was significantly greater than 38 
that of a bolus delivered through a commercial cath eter (+16.5%, p<0.05), suggesting better delivery o f 39 
insulin into the adjacent tissue and vasculature/ly mphatics. The JAPC furthermore evaluated tissue 40 
response to Achilles cannulas by [CONTACT_171680]. The inflammatory layer 41 
(thrombus, inflammatory cells, collagen, debris, pr oteins, etc.) was consistently thinner around CapBi o 42 
cannulas compared with the commercial Silhouette ov er 8 days of wear time (p<0.001). The overall area 43 
of inflamed tissue surrounding the CapBio cannula w as significantly larger around Silhouette control 44 
catheters compared to the Achilles cannula between 4 and 8 days of wear time (p=0.003). A publication 45 
of a head-to-head comparison of the Achilles infusi on set and a commercial infusion set with a 90Â° 46 
cannula is currently in preparation. The methods ha ve been published in 2019 together with results 47 
showing significantly better tissue response when u sing angled cannulas.14 48 
1.1.3  Human Use of the Capi[INVESTIGATOR_171656] 49 
Feasibility Study 50 
This was a prospective non-randomized home use feas ibility study of the manually inserted Achilles 51 
device (previous version of the SteadiSet) performa nce, usability, tolerability and safety in patients  with [ADDRESS_201269]. Vince ntâ€™s Hospi[INVESTIGATOR_307], Melbourne, Australia, under principa l 53 
investigator [CONTACT_171705] Oâ€™Neal. The study was comp osed of 3 periods with each period initiated at the  54 
CRU and followed by a home-use phase of up to 7 day s. A run-in period (Week 1) was followed by [CONTACT_1192] [ADDRESS_201270] periods (Week 2 and Week 3) in which subjects discontinued the use of their routine IIS and manag ed [ADDRESS_201271] wore the Achilles 58 
for the total 7-day wear period. Twenty subjects co mpleted the study and a total of 41 infusion sets w ere 59 
inserted in Week 2 and Week 3. The overall 7-day su rvival rate for the infusion sets was 88% (36/41). 60 
Proportional time spent with glucose <3.9 mmol/L di d not increase while wearing the Achilles infusion 61 
set. 62 
A total of 23 adverse events were reported from 15 (75%) of subjects. The most common adverse events 63 
included: hyperglycemia (35%) and infusion/insertio n site reactions (35%). There were no serious or 64 
unanticipated adverse events from this investigatio n. Overall, the Achilles infusion set was safe and well 65 
tolerated for and extended wear time. Results publi shed Kastner JR, Venkatesh N, Brown K, Muchmore 66 
DB, Ekinci E, Fourlanos S, Joseph JI, Shafeeq M, Sh i L, Strange P, Strasma PJ, O'Neal DN. Feasibility 67 
study of a prototype extended-wear insulin infusion  set in adults with type 1 diabetes. Diabetes Obes 68 
Metab. 2022 Jun;24(6):1143-1149. doi: 10.1111/dom.1 4685. Epub 2022 Mar 18. PMID: 35257468. 69 
PK/PD Study 150-1022-[ADDRESS_201272] crossover study to assess the Achill es 71 
deviceâ€™s performance, survivability, consistency, e fficacy, and safety over an extended wear time of u p 72 
to 7 days. Pharmacokinetic (PK) and pharmacodynamic  (PD) profiles of a bolus of rapid-acting insulin 73 
were measured on 4 separate days of IIS wear time d uring 2 separate wear periods. Following a wash-out  74 
period, subjects crossed over into the investigatio nal or control group, respectively. Seven subjects 75 
enrolled and six subjects completed the study at th e Advanced Metabolic Care + Research (AMCR) [ADDRESS_201273] shown that insulin 80 
exposure is accelerated as wear time increases over  7 days of infusion set use. Further, the results o f this 81 
small study are supportive of the conclusion that t he Achilles IIS reliably delivers insulin and facil itates 82 
maintenance of satisfactory glucose control over 7 days. Given the progressive acceleration of insulin  83 
exposure over the 7-day wear period, it may be that  the deployment of an automated insulin delivery 84  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 21 OF 59 system may help to automatically match insulin deli very to insulin requirements across infusion set we ar 85 
time. Results published in a brief report: Kastner JR et.al Progressive acceleration of insulin exposu re 86 
over 7 days of infusion set wear. Diabetes Technol Ther. 2202 Dec 20.doi:10.89/dia 2022.0323. 87 
Pi[INVESTIGATOR_16116] 150-1139-00 88 
This study was designed as a controlled, random-seq uence, single-center study of device performance, 89 
tolerability, and safety of the SteadiSet infusion set compared to a commercially available Teflon con trol 90 
device during four home use periods of up to 14 day s each (AABB vs. BBAA). The primary endpoint of 91 
this study was the duration (days) of successful in sulin delivery through the SteadiSet before removal  due [ADDRESS_201274]. Julia Made r. There were no unexpected or serious adverse even ts. 95 
Results published: Kastner, Jasmine R., PhD. et. al . Current insulin infusion set failure criteria may  be too 96 
stringent for real-life settings and may skew infus ion set failure outcomes in extended-wear infusion set 97 
studies. Diabetes, Obesity and Metabolism 08 Decemb er 2022, https://doi.org/10.1111/dom.[ZIP_CODE]. 98 
1.2 Objective and Rationale 99 
The objective of this prospective, multi center, si ngle-arm study is to assess the efficacy, safety, a nd 100 
tolerability of using the SteadiSet infusion set fo r insulin delivery when each set is used continuous ly for 101 
up to 7 days in adults with T1D, to provide data fo r regulatory submission. 102 
The rationale for the study is based on the aforeme ntioned literature that has documented that high fa ilure 103 
rate with currently available infusion sets and the  promising preliminary data indicating that the Ste adiSet 104 
infusion set may fail less frequently and function longer. 105 
1.3 Endpoints 106 
1.3.1  Primary Efficacy Endpoint 107 
Percentage of successfully inserted SteadiSet infus ion sets (i.e., not removed within 8 hours of inser tion) 108 
that are not withdrawn from use prior to 7 days (16 8 hours) due to either (1), (2), or (3):  109 
1. Blood Glucose value â‰¥250 mg/dL with ketones >1.0 mm ol/L, in the absence of illness or other 110 
physiological stress.  111 
2. Blood Glucose value â‰¥250 mg/dL for at least [ADDRESS_201275] 50 mg/dL. [ADDRESS_201276]â€™s safety 115 
1.3.2  Safety Endpoints 116 
The incidence, severity, and relationship to the in vestigational device of all reported adverse events  117 
(serious and non-serious including DKA and severe h ypoglycemia) from day of insertion through day 118 
of device removal for each wear period. 119 
1.3.3  Key Secondary Endpoint 120 
Proportion (%) of SteadiSet infusion sets withdrawn  from use at any time following insertion prior to 7 121 
days (168 hours) as evidenced by [CONTACT_171681]. NOTE: infusion set  122 
removals prior to 168 hours due to miscalculation o f date and/or time, along with other removals that 123 
cannot be ascribed to the investigational device pe rformance, are excluded from this proportion 124 
calculation.  125  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 22 OF 59 1. Infusion set failure as defined in the Primary Endp oint (including any such removals occurring [ADDRESS_201277] 8 hours following set insertion) 127 
2. Evidence of infusion set site infection defined as requiring treatment or at the investigatorâ€™s 128 
judgment 129 
3. Cannula dislodgement from subcutaneous (SC) space ( with or without liquid leakage at the 130 
cannula insertion site) [ADDRESS_201278] 133 
b. Accidental removal events (e.g., tubing caught on d oorknob) are excluded from this 134 
proportion calculation 135 
4. Occurrence of a non-resolvable pump occlusion alarm  136 
5. Other device malfunction (e.g., inability to pi[INVESTIGATOR_171645], bending, or other malformation that might [ADDRESS_201279] insulin infusion, securement failure) [ADDRESS_201280] tolerability levels for the infusion set in sertion as assessed by a pain scale of 0 to 100 147 
with zero being no pain and 100 being significant p ain 148 
4. Hyperglycemia trends in days 1-3 versus after day 3  149 
5. Infusion set performance (including set failures as  defined above and also glucose metrics, 150 
insulin doses, pump occlusion alarms and hyperglyce mia trends) in subjects who use low doses 151 
(e.g., <25 units/day) of insulin and in subjects wh o experience frequent stops and start of pump [ADDRESS_201281] Hyperglycemia Management and Infusion Set R emoval 156 
Guidelines 157 
1. If, in the absence of illness or other physiologica l stress, blood glucose is â‰¥250 mg/dL and 158 
ketones are >1.0 mmol/L, then infusion set failure is established.* 159 
o Ketones are to be measured any time the blood gluco se value is â‰¥250 mg/dL [ADDRESS_201282] ket ones hourly until ketones fall below 161 
0.6 mmol/L. 162  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 23 OF 59 2. If the CGM glucose value is â‰¥250 mg/dL for 60 minut es or longer, 3 hours or more following a 163 
snack or meal event AND ketones measure â‰¤1.0 mmol/L  then attempts to correct the 164 
hyperglycemia are to occur as follows: 165 
o Confirm the blood glucose value is >250 mg/dL with a fingerstick BG value. 166 
o If this fingerstick BG value is <250 mg/dL the subj ect will be instructed to continue 167 
to follow CGM readings. 168 
ï‚· If confirmatory fingerstick BG value is â‰¥250 mg/dL then an initial manual correction bolus 169 
delivered by [CONTACT_171682].  170 
ï‚· 60 minutes from the initial correction bolus (not t he time of an auto bolus) will start the 171 
hourly testing schedule for fingerstick BGs and ket ones. If the repeat ketone level after the 172 
initial correction bolus is â‰¤1.0 mmol/L, and the gl ucose has not fallen by 50 mg/dL then a 173 
second correction bolus should be administered usin g the same procedures described above. 174 
(The manual correction bolus dose given from the Bol us Calculator the subject administers [ADDRESS_201283] ) 176 
o If a repeat fingerstick BG value shows failure to r espond to the second correction 177 
bolus within an additional hour with a fall of 50 m g/dL from the fingerstick BG prior 178 
to initial correction bolus and there has been no intervening snack or meal eve nt, 179 
then the infusion set failure is established.* [ADDRESS_201284] 50 mg/dL from the fingerstick BG prior to the  initial correction bolous AND the 182 
fingerstick BG is still â‰¥250 mg/dL then fingerstick  BGs and ketone levels should be 183 
rechecked hourly until the fingerstick BG level fal ls below 250 mg/dL.  184 
o If fingerstick BG does not fall below 250 mg/dL wit hin six (6) hours from initial 185 
hyperglycemic event (i.e., 9 hours after a meal eve nt) infusion set failure is 186 
established*.  187 
o If the ketone level measures >1.0 mmol/L at any of these hourly rechecks, then the [ADDRESS_201285] failed.* 189 
*If the above scenarios occur prior to [ADDRESS_201286] been contact[INVESTIGATOR_530] ( either during the infusion set change 197 
procedure or afterwards), they will conduct a struc tured interview and document the relevant [ADDRESS_201287] the set. In no case should the set  be worn beyond 192 hours of use.  201 
1.5 Potential Risks and Benefits of the Investigational  Device System 202 
Risks and benefits are detailed below. Loss of conf identiality is a potential risk; however, data are 203 
handled securely to minimize this risk. Hypoglycemi a and hyperglycemia are always a risk in subjects 204 
with type 1 diabetes and insulin treatment, and sub jects will be monitored for this. 205  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 24 OF 59 The SteadiSet device has been analyzed for possible  hazards using the methods in ISO [ZIP_CODE]:2012 206 
Medical Devices, Application of Risk Management to Medical Devices. Capi[INVESTIGATOR_171657]. 207 
considers SteadiSet to be adequately safe to justif y its use in clinical trials based on the benefits compared 208 
to overall risk. 209 
1.5.1  Known Potential Risks 210 
[IP_ADDRESS]  Risk of Hypoglycemia 211 
As with any person having type 1 diabetes and using  insulin, there is always a risk of hypoglycemia. 212 
The frequency of hypoglycemia should be no more tha n it would be as part of daily living. Symptoms 213 
of hypoglycemia can include sweating, jitteriness, and not feeling well. Severe hypoglycemia is possib le 214 
with loss of consciousness or seizures. Recurrent h ypoglycemia may reduce hypoglycemia awareness. 215 
A CGM functioning poorly and significantly over-rea ding glucose values could lead to inappropriate 216 
insulin delivery. 217 
[IP_ADDRESS]  Risk of Hyperglycemia 218 
Hyperglycemia and ketonemia could occur if insulin delivery is attenuated or suspended for an extended  219 
period or if the pump or infusion set is not workin g properly. A poorly functioning CGM significantly 220 
under-reading blood glucose values could lead to in appropriate suspension of insulin delivery. 221 
[IP_ADDRESS]  Insulin Infusion Risks 222 
The study infusion set is inserted under the skin. Infection can occur very infrequently, but, if an i nfection 223 
was to occur, oral and/or topi[INVESTIGATOR_171658] b e used to treat the infection. 224 
Examples of possible infusion site reactions includ e: localized pain, bleeding, bruising, induration, 225 
infection, itching/pruritus, purulence, reddening ( erythema), swelling, and other non-specified irrita tion. 226 
Infusion set failure may occur, leading to hypergly cemia or ketosis. The risk for infusion set failure  may 227 
be increased in this study because sets are worn fo r an extended period. Examples of insulin infusion 228 
failure modes include: clogs, accidental removal, i nsulin leak from site, insulin leak from set or tub ing, 229 
adhesive failure, cannula insertion failure (not al l holes below epi[INVESTIGATOR_49196]), incomplete tubing prime, 230 
incomplete cannula prime, air bubbles in tubing, in adequate insulin pump/cartridge/infusion set 231 
connection, and cannula inserted too deep. 232 
[IP_ADDRESS]  Risks of Use of Insulin Pump with Automated Insulin  Delivery 233 
CGM sensor readings higher or lower than the actual  blood glucose level increases the risk for 234 
hypoglycemia and hyperglycemia with use of automate d insulin delivery systems. 235 
Algorithm or other device malfunctions could produc e a suspension of insulin delivery or over-delivery  of 236 
insulin which increases risk for hyperglycemia and hypoglycemia. 237 
[IP_ADDRESS]  Fingerstick Risks 238 
About 1 drop of blood will be removed by [CONTACT_171683] k for measuring HbA1c or doing other tests. Pain is  239 
common at the time of lancing. In about 1 in 10 cas es, a small amount of bleeding under the skin will 240 
produce a bruise; a small scar may persist for seve ral weeks. The risk of local infection is less than  1 in 241 
1000. This should not be a significant contributor to risks in this study as finger sticks are part of  the usual 242 
care for people with diabetes. 243  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 25 OF 59 [IP_ADDRESS]  CGM Subcutaneous Catheter Risks 244 
Use of CGM has a low risk for developi[INVESTIGATOR_007] a local sk in infection at the site of the sensor needle 245 
placement. There may be bleeding where the catheter  is put in and bleeding under the skin causes a 246 
bruise (1 in 10 risk). [ADDRESS_201288] a  small portion of the sensor under the skin that ma y 248 
cause redness, swelling or pain at the insertion si te. 249 
[IP_ADDRESS]  Risks Associated with Device Reuse 250 
In this study, device components (CGM, BG meter, or  ketone meter) will not be reused between different  251 
subjects. 252 
[IP_ADDRESS]  Rapid-Acting Insulin Analog Adverse Reactions [ADDRESS_201289] be current users of rapid-actin g insulin analogs at the time of enrollment (i.e., 254 
completion of consent documentation). Therefore, th e risk of adverse reactions to commercially availab le 255 
rapid-acting insulin used during the study should b e very low, but development of the following 256 
conditions is possible: anaphylaxis, antibody produ ction, hypokalemia, lipodystrophy, peripheral edema , 257 
renal or hepatic impairment, and weight gain. 258 
[IP_ADDRESS]  Questionnaire-Associated Risks [ADDRESS_201290] been uncommon. 263 
[IP_ADDRESS]  Other Risks [ADDRESS_201291]â€™s pump, CGM and stud y blood glucose and ketone meter will be collected 267 
for the study as measures of diabetes self-manageme nt behaviors. Some people may be uncomfortable 268 
with the researchers' having such detailed informat ion about their daily diabetes habits. 269 
There may be other risks that are unknown at this t ime and new risks that may be identified during the  270 
study. 271 
The infusion set has not been tested with radiation  therapy or an MRI procedure. The infusion set shou ld 272 
be removed before radiation therapy or an MRI proce dure.  273 
1.5.2  Known Potential Benefits 274 
Study participation may not provide any immediate b enefit to study subjects. However, results of this 275 
research may result in the following potential bene fits to the study subjects or to future patients wi th 276 
diabetes: 277 
ï‚§ Development of an extended wear insulin infusion se t 278 
ï‚§ Reduction in the number of required infusion set in sertions and number of infusion sites 279 
ï‚§ Reduction in infusion site (skin/tissue) reactions 280 
ï‚§ Improved glucose control (e.g., more stable insulin  kinetics) 281  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 26 OF 59 ï‚§ Improved Continuous Subcutaneous Insulin Infusion ( CSII) and insulin pump therapy options 282 
ï‚§ Reduced environmental waste [ADDRESS_201292] benefi t to 286 
individual subjects, but likely to yield generaliza ble knowledge about the subjectsâ€™ disorder or condi tion. [ADDRESS_201293] their origin in the Declaration of Helsinki, with the protocol d escribed 290 
herein, and with the standards of Good Clinical Pra ctice (GCP). 291 
The protocol is considered a significant risk devic e study since the study infusion set is experimenta l. 292 
Therefore, an investigational device exemption (IDE ) from the U.S. Food and Drug Administration 293 
(FDA) is required to conduct the study. 294  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 27 OF 59 Chapter 2:  Study Enrollment and Screening [ADDRESS_201294] Recruitment and Enrollment 296 
Enrollment will proceed with the goal of 240 subjec ts (120 each on insulins lispro and aspart) complet ing [ADDRESS_201295] inquiry (e.g.,  resulting from IRB-approved recruiting materials) or a [ADDRESS_201296] will be provided with t he Informed Consent Form to read and will be given 312 
the opportunity to ask questions either in-person, via phone/videoconference, or by [CONTACT_65056]. If the [ADDRESS_201297]â€™s study record. [ADDRESS_201298] 3 months of current experience 333 
with a Tandem pump 334  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 28 OF 59 6. Using Tandem t:slim X2 insulin pump with Control-IQ  technology for a minimum of [ADDRESS_201299] 85% of time with  Control-IQ technology active  338 
8. HbA1c <9.0% in the last 6 months 339 
9. Willing to implement and adhere to pump alert/alarm  settings on a study-provided pump as 340 
instructed during the study 341 
10. Willing to wear each investigational infusion set f or up to 7 days during each of the 12 342 
consecutive wear periods in the study 343 
11. Willing to perform  blood ketone and blood glucose (fingerstick) measurements as directed using 344 
provided ketone and blood glucose meters and strips  345 
12. Access to internet for required periodic uploads of  study device data 346 
13. BMI in the range 18â€“35 kg/m2, both inclusive 347 
14. Currently using one of the following insulins with no expectation of a need to change insulin type 348 
during the study: 349 
a. Humalogâ„¢ (insulin lispro) 350 
b. NovoLogâ„¢ (insulin aspart) 351 
15. Using Humalogâ„¢ insulin lispro or NovoLogâ„¢ insulin a spart for a minimum of 1 month at the 352 
time of enrollment  353 
16. Willing to change insulin cartridge every 48-72 hou rs, as recommended by [CONTACT_4676]â€™s healthcare 354 
provider during the study 355 
17. Has routine access to a smart phone e.g., ability t o receive text messages  356 
18. Has the ability to understand and comply with proto col procedures and to provide informed 357 
consent (i.e., English proficient in both verbal an d written communication) [ADDRESS_201300] Exclusion Criteria 359 
Individuals meeting any of the following exclusion criteria at baseline will be excluded from study 360 
participation. 361 
1. Concurrent use of any non-insulin glucose-lowering agent, other than metformin (for example, 362 
GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 in hibitors, sulfonylureas) [ADDRESS_201301] 6 month s resulting in: 366 
a. Medical Assistance (i.e., paramedics, hospi[INVESTIGATOR_307] e valuation or hospi[INVESTIGATOR_059]) 367 
b. Loss of consciousness 368 
c. Seizures 369 
4. One or more epi[INVESTIGATOR_171648] (DKA)  in the last 6 months requiring 370 
hospi[INVESTIGATOR_059] 371 
5. Currently on a ketogenic or low-carbohydrate diet o f less than 60 grams of carbohydrates per day, 372 
or intending to begin one during the study period 373  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 29 OF 59 6. Known cardiovascular disease considered to be clini cally relevant by [CONTACT_093] 374 
7. Known history of any of the following conditions: 375 
a. Cushingâ€™s Disease 376 
b. Pancreatic islet cell tumor 377 
c. Insulinoma 378 
d. Lipodystrophy 379 
e. Extensive lipohypertrophy, as assessed by [CONTACT_34462] 380 
8. Currently undergoing treatment with: 381 
a. Systemic oral or intravenous corticosteroids (cu rrent or within the last 8 weeks from 382 
screening), [ADDRESS_201302] 3 months 384 
9. Significant history of any of the following, that i n the opi[INVESTIGATOR_171659] 385 
compromise safety or successful study participation : 386 
a. Alcoholism 387 
b. Drug abuse 388 
10. Significant acute or chronic illness, that in the o pi[INVESTIGATOR_171660] 389 
safety or integrity of study results 390 
11. Current participation in another clinical drug or d evice study 391 
12. Immediate family member (spouse, biological or lega l guardian, child, sibling, parent) who is a 392 
study site personnel directly affiliated with this study or who is an employee of Capi[INVESTIGATOR_1396] 393 
Biomedical 394 
2.4 Eligibility Assessment and Baseline Data Collection  395 
Potential subjects will be evaluated for study elig ibility through the elicitation of a medical histor y and 396 
local laboratory testing as needed in the judgment of the investigator (as part of usual care). [ADDRESS_201303] or 399 
investigatorâ€™s preference for a remote visit. Study  staff will discuss the feasibility of conducting v irtual [ADDRESS_201304] e nrollment (i.e., completion of consent documentatio n). [ADDRESS_201305]â€™s diabetes history, current diabetes ma nagement, other past and current medical problems, [ADDRESS_201306]â€™s primary diabetes provider, for e xample, via a phone call or videoconference between  408 
the enrolling investigator and the current provider . 409 
2.6 Screening Testing and Procedures 410 
At the Screening Visit the following procedures wil l be performed/information will be elicited: 411  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 30 OF 59 ï‚§ Assessment of eligibility 412 
ï‚§ Demographics (date of birth, gender, race, and ethn icity) 413 
ï‚§ Contact [CONTACT_3031] (retained at the site and provi ded to Coordinating Center to allow 414 
automated text or email messages during study) 415 
ï‚§ Medical history as described above in Section 2.4 416 
ï‚§ Substance use history (drinking, smoking, and drug habits) 417 
ï‚§ Current medications 418 
ï‚§ Measurement of height/weight 419 
ï‚§ If the visit is conducted virtually, a verbal repor t of the subjectâ€™s weight and verbal 420 
report of height will be acceptable. 421 
ï‚§ Urine pregnancy test for all women who have reached  menarche and are premenopausal 422 
and are not surgically sterile. 423 
ï‚§ If the visit is conducted virtually, a negative uri ne pregnancy test result from a test kit [ADDRESS_201307] may be confirmed via teleconfer ence. 425 
ï‚§ Determination of adherence to Control-IQ use in the  [ADDRESS_201308]â€™s  personal t:connect account .  427 
ï‚§ Subjects must have had Control-IQ technology active  at least 85% of the time during 428 
the 14 days before screening to be eligible to cont inue in the study. 429 
ï‚§ Verification HbA1c is <9.0% in the last 6 months.  430 
ï‚§ Completion of the Usability, Satisfaction & Prefere nce Survey (study web site link sent to [ADDRESS_201309]) to evaluate subjectâ€™s experience with the insertion and daily wear of their current 432 
infusion set before exposure to the study infusion set. 433 
ï‚§ Subject demonstrates proficiency in following study  procedures. [ADDRESS_201310] approximately 2 hour s. 435 
2.7 Screen Failures 436 
Individuals who do not initially meet study eligibi lity requirements, such as required Control-IQ 437 
adherence or estimated HbA1c value, may be rescreen ed once while study enrollment is still open. 438  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 31 OF 59 Chapter 3:  Main Study [ADDRESS_201311] either in-person at the clinic or via delivery  by [CONTACT_39785] 444 
means (personal delivery, overnight shipment, etc).  445 
Before dispensing, BG and ketone meters will be QC tested with control solution to verify readings are  446 
within the target range per manufacturer labeling. 447 
Study subjects will be provided with a Tandem t:sli mX2 with Control-IQ insulin pump to use in the stud y [ADDRESS_201312] 's personnel profile settings. Subjects will contin ue to use 450 
their personal Dexcom G6 or G7 CGM system. Subjects  may switch between G6 and G7 sensors during 451 
the course of the study and will be instructed to o nly do so at the time of insertion of a new study i nfusion 452 
set.  453 
The Tandem t:connect mobile app will not work with the study insulin pumps. Subjects will upload study  [ADDRESS_201313]â€™s capil lary 458 
collection, supplies will be provided to the subjec t within 3 days of the Study Infusion Set Initiatio n Visit. 459 
Collection of HbA1c may occur either in-person at t he clinic, or via delivery by [CONTACT_11174] (personal  460 
delivery, overnight shipment, etc.). 461 
3.1.2  Study Infusion Set Training and Initiation 462 
Subjects will be trained (in-person or via videocon ference) on how to insert the SteadiSet infusion se t. 463 
The initial insertion will be observed either in pe rson or on video during a virtual visit.  464 
Subjects who are unable to insert the SteadiSet wit hin 3 attempts will be dropped from study 465 
participation.  466 
Points of training will include the following: 467 
ï‚§ Subjects will be advised to avoid inserting the Ste adiSet device in places that may cause 468 
pressureâ€”e.g., under a belt or snug waist band.  469 
ï‚§ Subjects will be advised to closely monitor their C GM for the first [ADDRESS_201314] will be instructed to call the study center  for guidance. 472 
ï‚§ Subjects will be given guidelines with detailed pro cedures on what to do if prolonged elevated [ADDRESS_201315] occurred (Section 3.2). 474 
ï‚§ Subjects will be instructed to contact [CONTACT_171684] 475 
worn for less than 7 full days.  476 
ï‚§ Subjects will be instructed to retain all parts of the used infusion set and label and return to the 477 
clinic. 478  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 32 OF 59 ï‚§ Subjects will be instructed to insert a new sequent ial infusion set following removal of each prior [ADDRESS_201316] the target of 12 infusion  sets worn. 481 
ï‚§ Subjects will be instructed to change the insulin c artridge every 48-72 hours, as recommended by 482 
their healthcare provider. 483 
ï‚§ Subjects will be instructed to change their insulin  cartridge and infusion set independent of each [ADDRESS_201317] study site if there is concern about infusi on set failure. 486 
ï‚§ Subjects will be required to upload insulin pump da ta (which includes both insulin dosing and 487 
CGM data). This will be performed remotely for virt ual visits or in clinic for face-to-face visits. 488 
Ketone and BG meters will be uploaded during face-t o-face visits.  489 
ï‚§ Subjects who have only virtual visits will be provi ded with three ketone and BG meters each, and 490 
will be instructed to mail the meters to the study site at week 2, week 6 and final visits. 491 
3.2 Hyperglycemia Management Guidelines 492 
The study pumpâ€™s Control-IQ High Alert, which canno t be disabled, will alert the subject when there is  493 
a CGM reading >200 mg/dL and no prediction the CGM will decrease in the next 30 minutes. 494 
The study pumpâ€™s optional CGM High Alert will be co nfigured by [CONTACT_171685] a threshold of 495 
250 mg/dL and a Repeat setting of [ADDRESS_201318] the â€œout of rangeâ€ alert set for  20 minutes (shortest possible setting) to reduce r isk of 498 
missing data. The pump â€œlow insulin alertâ€ will be set at â‰¥ 20 units to reduce risk of running the pum p on 499 
an empty cartridge. It is recommended to set the Au to Off Alert to OFF. Site Reminder alert may be set  to 500 
ON to remind subjects to change their cartridge but  not their infusion set.  501 
Subjects will be instructed not to modify the alert  settings configured by [CONTACT_171686] 502 
above. 503 
Subjects will receive training on how to address Oc clusion alarm #1 (resolvable alarm) and Occlusion 504 
alarm #2 (non-resolvable alarm) requires infusion s et change. [ADDRESS_201319] the following scheduled follow-u p visits and phone contacts as follows: 517  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-[ADDRESS_201320] TYPE TARGET/ 
ALLOWABLE WINDOW 
(AROUND TARGET DAY/WEEK) 
3 Days Phone -1 to +3 days 
2 Weeks Clinic/Virtual  Â± 4 days 
6 Weeks Clinic/Virtual Â± 7 days 
Final Visit (completion of 
12th wear period or 
termination) Clinic/Virtual  + [ADDRESS_201321] of the study. Additional visits ca n 524 
occur as needed. 525 
3.5.1  Procedures at Study Visits 526 
[IP_ADDRESS]   Day 3 527 
ï‚§ Assessment of compliance with guidelines for Steadi Set device use  528 
ï‚§ Assessment of adverse events, adverse device effect s, and device issues 529 
ï‚§ Review key aspects of study protocol regarding infu sion set failure 530 
[IP_ADDRESS]   Week 2  531 
Procedures are identical to those above for the 3-D ay visit with the addition of: 532 
ï‚§ Completion of the Usability, Satisfaction & Prefere nce Survey (study web site link sent to [ADDRESS_201322]) to evaluate subjectâ€™s experience with the insertion and daily wear of the SteadiSet 534 
infusion set. 535 
ï‚§ Upload Ketone and BG meters 536 
[IP_ADDRESS]   Week 6  537 
Procedures are identical to those above for the 3-D ay visit, with the addition of: 538 
ï‚§ Upload Ketone and BG meters 539 
[IP_ADDRESS]   Final Visit 540 
The following will occur. 541 
ï‚§ Upload Ketone and BG meters 542 
ï‚§ Assessment of adverse events, adverse device effect s, and device issues 543  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 34 OF 59 ï‚§ Completion of the Usability, Satisfaction & Prefere nce Survey (study web site link sent to [ADDRESS_201323]) to evaluate subjectâ€™s experience with the insertion and daily wear of the SteadiSet 545 
infusion set. 546 
ï‚§ A capi[INVESTIGATOR_171661]-o f-study HbA1c determination. Capi[INVESTIGATOR_1396] [ADDRESS_201324]  as described above, before the Final Visit so 548 
that sample collection can occur during the Final V isit. 549 
ï‚§ Collection of all used and unused (as applicable) S teadiSet devices, ancillary supplies and study [ADDRESS_201325] completed all study protocol req uirements at the end of the 12th wear period (Wear 553 
Period 12) regardless of actual total days of Stead iSet infusion set wear. Subject will return to usin g their 554 
personal pump and routine insulin infusion sets at the completion of their participation in the study.  555 
3.5.3  Early Study Discontinuation 556 
Subjects who discontinue the study prior to the 12th infusion set wear period either by [CONTACT_171687] 557 
investigator decision, will be asked to complete th e end of study visit as outlined in Final Visit Sec tion 558 
[IP_ADDRESS]. 559  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 35 OF 59 Chapter 4:  Study Devices 560 
4.1 Description of the Investigational Device: SteadiSe t Infusion Set 561 
The Capi[INVESTIGATOR_171642], Inc. (CapBio) SteadiSet I nfusion Set (SteadiSet device) is a sterile single use 562 
device for continuous subcutaneous insulin infusion  (CSII). SteadiSet Infusion Sets are designed to be  [ADDRESS_201326] connection; this will limit pump use to only  564 
Tandem t:slim X2 insulin pumps. The investigational  SteadiSet Infusion Set contains a coil reinforced 565 
soft polymer indwelling cannula with one distal and  three proximal holes. This cannula is deployed int o 566 
subcutaneous tissue via an integrated single use in sertion device (inserter). Figure 2 The SteadiSet 567 
consists of an (A) insertion mechanism, hub holding  the cannula in place, and (B) pump-specific tubing  [ADDRESS_201327] tubing (43 inc h) will be used. The SteadiSet Infusion Set, with 569 
cannula, insertion mechanism, and tubing, is indivi dually packaged and sterilized in a vacuum formed c up 570 
with a Tyvekâ„¢ lid. 571 
 572 
Figure 2. Components of the SteadiSet Infusion Set 573 
 574 
A. Cartridge connector 575 
B. Set connector 576 
C. Inserter 577 
D. Set with cannula (inside inserter) [ADDRESS_201328] cover 580 
G. Set  581 
For this clinical trial subjects will be exposed to  the device for 12 consecutive wear periods of up t o 582 
7 days each. Devices will be returned to the study site at the end of study participation, defined as after 583 
12 wear periods or end of their study participation  regardless of the number of wear periods. 584 
4.2 Insulin Pump 585 
Subjects will be provided with a Tandem t:slim X2 p ump with Control-IQ technology and insulin [ADDRESS_201329] lancets and alcohol wipes.      594 
G  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-[ADDRESS_201330] Access to Study Devices at Study Closure 602 
Subjects will return the study pump and all used an d unused study infusion sets. Subjects may keep the  603 
ancillary supplies, BG and ketone meters once confi rmation all data has been uploaded into study 604 
database. 605  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 37 OF 59 Chapter 5:  Testing Procedures and Questionnaires [ADDRESS_201331] results will be reported to the study center  per the 614 
clinical siteâ€™s standard procedures. 615 
5.2 Questionnaires 616 
5.2.1  Screening Visit 617 
Study personnel will ask subjects to complete a Usa bility, Satisfaction & Preference Survey with 618 
multiple-choice questions and optional comment area s about their experience with their current insulin  619 
infusion set during their Screening Visit. The surv ey takes approximately 5 to 10 minutes to complete.   620 
5.2.2  Week 2 Visit 621 
Study personnel will ask subjects to complete a Usa bility, Satisfaction & Preference Survey with [ADDRESS_201332] two Wear Periods. The sur vey should take approximately 5 to 10 minutes to 624 
complete. 625 
5.2.3  Final Visit 626 
Study personnel will ask subjects to complete a Usa bility, Satisfaction & Preference Survey with 627 
multiple-choice questions and optional comment area s about their experience with the SteadiSet infusio n 628 
set following their final Wear Period. The survey s hould take approximately 5 to 10 minutes to complet e. 629  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 38 OF 59 Chapter 6:  Unanticipated Problem, Adverse Event, and [ADDRESS_201333] report Unanticipated Problems to the 634 
IRB within seven (7) calendar days of recognition. Sites using other IRBs will follow their reporting [ADDRESS_201334] be reported to the Coordinating Center 636 
within 24 hours of learning of the events. For this  protocol, an unanticipated problem is an incident,  637 
experience, or outcome that meets all of the follow ing criteria: 638 
ï‚§ Unexpected (in terms of nature, severity, or freque ncy) given (a) the research procedures that are 639 
described in the protocol related documents, such a s the IRB-approved research protocol and 640 
informed consent document; and (b) the characterist ics of the subject population being studied 641 
ï‚§ Related or possibly related to participation in the  research (possibly related means there is a [ADDRESS_201335] been caused by [CONTACT_941] 643 
procedures involved in the research) 644 
ï‚§ Suggests that the research places subjects or other s at a greater risk of harm than was previously 645 
known or recognized (including physical, psychologi cal, economic, or social harm) [ADDRESS_201336] be reported to the JCHR IRB within seven  649 
(7) calendar days of recognition. The Director of t he Human Research Protection Program (HRPP) will 650 
report to the appropriate regulatory authorities if  the IRB determines that the event indeed meets the  651 
criteria of an Unanticipated Problem requiring addi tional reporting to fulfill the reporting obligatio ns of 652 
the HRPP. 653 
6.2 Adverse Events 654 
6.2.1  Definitions 655 
Adverse Event (AE): Any untoward medical occurrence  (including laboratory findings) associated with 656 
study procedures, the use of a device, biologic, or  drug in humans, including any comparator used, 657 
whether or not the event is considered related (i.e ., irrespective of the relationship between the adv erse 658 
event and the device(s) under investigation). 659 
Serious Adverse Event (SAE): Any untoward medical o ccurrence that results in any of the following 660 
outcomes: 661 
ï‚§ Death. 662 
ï‚§ A life-threatening adverse event (a non-life-threat ening event which, had it been more severe, [ADDRESS_201337] become life-threatening, is not necessar ily considered a serious adverse event). 664 
ï‚§ Inpatient hospi[INVESTIGATOR_061]. 665 
ï‚§ A persistent or significant disability/incapacity o r substantial disruption of the ability to [ADDRESS_201338] normal life functions. 667 
ï‚§ A congenital anomaly or birth defect. 668 
An important medical event that may not result in d eath, be life-threatening, or require hospi[INVESTIGATOR_28689] 669 
may be considered serious when, based upon appropri ate medical judgment, may jeopardize the patient or  670  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-[ADDRESS_201339] and may require medical and/or surgical int ervention to prevent one of the outcomes listed in this 671 
definition. Note: If either the Sponsor or investig ator believes the event is serious, the event must be 672 
considered serious and evaluated by [CONTACT_171688]. See 21 CFR 812.3(s) for more [ADDRESS_201340] (UADE): Any ser ious adverse effect on health or safety or any [ADDRESS_201341], problem, or  676 
death was not previously identified in nature, seve rity, or degree of incidence in the investigational  plan 677 
or application (including a supplementary plan or a pplication), or any other unanticipated serious pro blem 678 
associated with a device that relates to the rights , safety, or welfare of subjects (21 CFR 812.3(s)).  [ADDRESS_201342] (ADE): Any untoward medical o ccurrence in a study subject which the device [ADDRESS_201343] con tributed. This definition includes adverse events 681 
resulting from insufficient or inadequate instructi ons for use, deployment, implantation, installation , or 682 
operation, or any malfunction of the investigationa l medical device; any event resulting from use erro r or 683 
from intentional misuse of the investigational medi cal device. (Note that an Adverse Event Form is to be 684 
completed in addition to a Device Deficiency or Iss ue Form, unless excluded from reporting as defined in 685 
Section 6.2). 686 
Device Complaints and Malfunctions: A device compli cation or complaint is something that happens to [ADDRESS_201344]. A device 688 
complaint may occur independently from an AE, or al ong with an AE. An AE may occur without a 689 
device complaint or there may be an AE related to a  device complaint. A device malfunction is any 690 
failure of a device to meet its performance specifi cations or otherwise perform as intended. Performan ce 691 
specifications include all claims made in the label ing for the device. The intended performance of a 692 
device refers to the intended use for which the dev ice is labeled or marketed. (21 CFR 803.3). Note: f or [ADDRESS_201345] inguish between device complaints and malfunctions.  694 
Use Error: User action or lack of user action while  using the medical device (3.34) that leads to a di fferent 695 
result than that intended by [CONTACT_171689]. Includes the inability of the u ser to 696 
complete a task. Use errors can result from a misma tch between the characteristics of the user, user 697 
interface, task or use environment. Users might be aware or unaware that a use error has occurred. An 698 
unexpected physiological response of the patient is  not by [CONTACT_3461] a use error. A malfunctio n of a 699 
medical device that causes an unexpected result is not considered a use error. (ISO [ZIP_CODE]:2020) [ADDRESS_201346] medical occurrence that meets one of 702 
the following criteria: [ADDRESS_201347]â€™s ability to complete any study 709 
procedures 710 
6. An AE as defined in Section 6.2.1 for which a visit  is made to a hospi[INVESTIGATOR_3409]  711 
7. Hypoglycemia meeting the reporting criteria defined  in Section 6.2.3 712 
8. Diabetic ketoacidosis (DKA) as defined below; or in  the absence of DKA, hyperglycemia or 713 
ketosis event meeting the reporting criteria in Sec tion 6.2.4 714  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-[ADDRESS_201348] or discontinuation of the study device. Skin reactions  716 
from sensor placement are only reportable if severe  and/or required treatment. 717 
All reportable AEsâ€”whether volunteered by [CONTACT_29320], discovered by [CONTACT_66708] [ADDRESS_201349], or other meansâ€”will be reporte d [ADDRESS_201350] is only reportable as an adverse event when 723 
one of the following criteria is met: 724 
A hypoglycemic event occurred meeting the following  definition of severe hypoglycemia: 725 
ï‚§ The event required assistance of another person due  to altered consciousness, and required [ADDRESS_201351] was impaired cognitivel y to the point that he/she was unable to 728 
treat himself/herself, was unable to verbalize his/  her needs, was incoherent, disoriented, 729 
and/or combative, or experienced seizure or loss of  consciousness. These epi[INVESTIGATOR_171662] 730 
be associated with sufficient neuroglycopenia to in duce seizure or loss of consciousness. 731 
If glucose measurements are not available during su ch an event, neurological recovery 732 
attributable to the restoration of glucose to norma l is considered sufficient evidence that the 733 
event was induced by a low glucose concentration. 734 
ï‚§ Evaluation or treatment was obtained at a health ca re provider facility for an acute event [ADDRESS_201352] contact[CONTACT_171690] e site and received guidance following 736 
the occurrence of an acute event involving hypoglyc emia. 737 
When a severe hypoglycemia event occurs (as defined  above), a Hypoglycemia Form should be [ADDRESS_201353] to reporting  requirements. When a severe hypoglycemia event 740 
occurs during use of a study device, it generally w ill be considered unrelated to the device if the de vice 741 
functioned as intended and there does not appear to  be a flaw in how the device is intended to functio n. 742 
6.2.4  Hyperglycemic/Ketotic Events [ADDRESS_201354] is only 746 
reportable as an adverse event when one of the foll owing criteria is met:  747 
ï‚§ The event involved DKA, as defined by [CONTACT_3467] 748 
(DCCT) and described below 749 
ï‚§ Evaluation or treatment was obtained at a health ca re provider facility for an acute event 750 
involving hyperglycemia or ketosis, or the particip ant contact[CONTACT_3466] 751 
guidance on how to manage the acute hyperglycemia/k etosis event unrelated to the infusion 752 
set 753 
ï‚§ Blood ketone level >1.5 mmol/L 754 
Hyperglycemic events are classified as DKA if the f ollowing are present: 755 
ï‚§ Symptoms such as polyuria, polydipsia, nausea, or v omiting; 756  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 41 OF 59 ï‚§ Serum ketones >1.5 mmol/L or large/moderate urine k etones; 757 
ï‚§ Either arterial blood pH <7.30 or venous pH <7.24 o r serum bicarbonate (or CO2) <15; and 758 
ï‚§ Treatment provided in a health care facility. 759 
When a hyperglycemia/ketotic event qualifies as a S AE as defined in Section 6.2.1, a 760 
Hyperglycemia/DKA Form should be completed in addit ion to the Adverse Event Form. Events meeting [ADDRESS_201355] to reporting requirements. 762 
Hyperglycemia events not meeting criteria for DKA g enerally will not be considered as serious adverse 763 
events unless one of the SAE criteria in Section 6. 2.1 is met. 764 
When a hyperglycemia/DKA event occurs during use of  a study device, it generally will be considered [ADDRESS_201356] udy 770 
device. The Medical Monitor also will make this ass essment, which may or may not agree with that of th e 771 
study investigator.  772 
To ensure consistency of adverse event causality as sessments, investigators should apply the following  773 
general guideline when determining whether an adver se event is related: 774 
Unrelated:  The AE is clearly not related to a study drug/devi ce and a likely alternative etiology 775 
exists such as an underlying disease, environmental  or toxic factors or other therapy. 776 
Unlikely Related:  The AE does not follow a reasonable temporal seque nce during or after use of 777 
study drug/device and a more likely alternative eti ology exists such as an underlying disease, 778 
environmental or toxic factors, or other therapy. 779 
Possibly Related:  The AE occurred in a reasonable time during or aft er use of study drug/device; 780 
but could be related to another factor such as an u nderlying disease, environmental or toxic factors, 781 
or other therapy; and there is a possible, though w eak, scientific basis for establishing a causal 782 
association between the AE and the study drug/devic e. 783 
Probably Related:  The AE occurred in a reasonable time during or aft er use of study drug/device; 784 
is unlikely to be related to another factor such as  an underlying disease, environmental or toxic 785 
factors, or other therapy; and there is a plausible , though not strong, scientific basis for 786 
establishing a causal association between the AE an d the study drug/device. 787 
Definitely Related:  The AE occurred in a reasonable time during or aft er use of study 788 
drug/device; cannot be explained by [CONTACT_3468], environmental 789 
or toxic factors, or therapy; and there is a strong  scientific basis for establishing a causal 790 
association between the AE and the study drug/devic e. [ADDRESS_201357] for 793 
relatedness and necessitate reporting as required ( see 21 CFR 812.3(s) for more information). 794 
6.2.6  Severity (Intensity) of Adverse Events 795 
The severity (intensity) of an adverse event will b e rated on a three-point scale: (1) mild, (2) moder ate, 796 
or (3) severe. A severity assessment is a clinical determination of the intensity of an event. Thus, a  severe 797  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 42 OF 59 adverse event is not necessarily serious. For examp le, itching for several days may be rated as severe , but 798 
may not be clinically serious. 799 
MILD: Usually transient, requires no special treatm ent, and does not interfere with the subjectâ€™s 800 
daily activities. 801 
MODERATE: Usually causes a low level of inconvenien ce, discomfort or concern to the subject [ADDRESS_201358] is able to continue in study. 804 
SEVERE: Interrupts a subjectâ€™s usual daily activiti es, causes severe discomfort, may cause 805 
discontinuation of study device, and generally requ ires systemic drug therapy or other treatment. 806 
6.2.7  Expectedness 807 
For a serious adverse event that is considered poss ibly related to study device, the Medical Monitor w ill 808 
classify the event as unexpected if the nature, sev erity, or frequency of the event is not consistent with 809 
the risk information previously described in the pr otocol or the Clinical Investigator Brochure. 810 
6.2.8  Coding of Adverse Events 811 
Adverse events will be coded using the MedDRA dicti onary. To facilitate coding, the site will enter a 812 
preliminary MedDRA code which the Medical Monitor m ay accept or change (the Medical Monitorâ€™s 813 
MedDRA coding will be used for all reporting). The Medical Monitor will review the investigatorâ€™s 814 
assessment of causality and may agree or disagree. Both the investigatorâ€™s and Medical Monitorâ€™s [ADDRESS_201359] the final say in determining the causality  as 816 
well as whether an event is classified as a serious  adverse event and/or an unanticipated adverse devi ce [ADDRESS_201360]. 818 
6.2.9  Outcome of Adverse Events 819 
The outcome of each reportable adverse event will b e classified by [CONTACT_3470]: 820 
RECOVERED/RESOLVED (COMPLETE RECOVERY) â€“ The subjec t recovered from the 821 
AE/SAE without sequelae. Record the AE/SAE stop dat e. 822 
RECOVERED/RESOLVED WITH SEQUELAE â€“ AE/SAE where the  subject recuperated but [ADDRESS_201361] the 824 
AE/SAE stop date. 825 
FATAL â€“ A fatal outcome is defined as the SAE that resulted in death. Only the event that was 826 
the cause of death should be reported as fatal. AEs /SAEs that were ongoing at the time of death; 827 
however, were not the cause of death, will be recor ded as â€œresolvedâ€ at the time of death. 828 
ONGOING (NOT RECOVERED/NOT RESOLVED) â€“ An ongoing A E/SAE is defined as an 829 
ongoing event with an undetermined outcome. 830 
ï‚§ An ongoing outcome will require follow-up by [CONTACT_171691] 831 
outcome of the AE/SAE. 832 
ï‚§ The outcome of an ongoing event at the time of deat h that was not the cause of death, will be 833 
updated and recorded as â€œresolvedâ€ with the date of  death recorded as the stop date. 834 
ONGOING (MEDICALLY STABLE) â€“ AE/SAE is ongoing, but  medically stable. For example, [ADDRESS_201362] completes the study (or withdraws), adverse [ADDRESS_201363] no  838  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-[ADDRESS_201364] has completed all applicable study 839 
visits/contacts. For all other adverse events, data  collection will end at the time the subject comple tes the 840 
study. Note: Subjects should continue to receive ap propriate medical care for an adverse event after t heir [ADDRESS_201365] not been met: 853 
ï‚§ Battery lifespan deficiency due to inadequate charg ing or extensive wireless communication 854 
ï‚§ Intermittent device component disconnections/commun ication failures not requiring system 855 
replacement or workaround/resolution not specified in user guide/manual. 856 
ï‚§ Device issues clearly addressed in the user guide m anual that do not require additional [ADDRESS_201366] be reported by [CONTACT_941] 860 
investigator to the Coordinating Center within twen ty-four (24) hours of the site becoming aware of th e 861 
event. This can occur via phone or email, or by [CONTACT_171692] d 862 
device issue form if applicable. If the form is not  initially completed, it should be competed as soon  as 863 
possible after there is sufficient information to e valuate the event. All other reportable ADEs and ot her 864 
reportable AEs should be submitted by [CONTACT_171693] (7) days of the site 865 
becoming aware of the event. 866 
The Coordinating Center will notify all participati ng investigators of any adverse event that is serio us, 867 
related, and unexpected. Notification will be made within ten (10) working days after the Coordinating  868 
Center becomes aware of the event. 869 
Each principal investigator [INVESTIGATOR_171663]-related adverse events and abid ing 870 
by [CONTACT_66716] /her Institutional Review Board or Ethics Committee . 871 
Where the JCHR IRB is the overseeing IRB, sites mus t report all serious, related adverse events within  872 
seven calendar days. 873 
Upon receipt of a qualifying event, the Sponsor wil l investigate the event to determine if a UADE has 874 
occurred, and if indicated, report the results of t he investigation to all overseeing IRBs, and the FD A 875 
within ten (10) working days of the Sponsor becomin g aware of the UADE per 21CFR 812.46(b) (2). The [ADDRESS_201367] ensure th at all investigations, or parts of investigations p resenting 878 
that risk, are terminated as soon as possible but n o later than five (5) working days after the Sponso r 879 
makes this determination and no later than fifteen (15) working days after first receipt notice of the  880  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 44 OF 59 UADE. The investigator(s) may then be required to p rovide approval or acknowledgment of receipt of [ADDRESS_201368] led to a UADE, including device deficiencies, irrespective of whether an adverse event occurred. 884 
6.5 Safety Oversight 885 
The study Medical Monitor will review all adverse e vents and adverse device events that are reported 886 
during the study. SAEs typi[INVESTIGATOR_171664] w ithin twenty-four (24) hours of reporting. Other AE s 887 
typi[INVESTIGATOR_3413] a weekly basis. Addit ionally, the Medical Monitor will review compi[INVESTIGATOR_42602] 888 
safety data at periodic intervals. 889 
The Clinical Study Director will be informed of all  cases of severe hypoglycemia and DKA and the 890 
Medical Monitorâ€™s assessment of relationship to the  study device; and informed of all reported device [ADDRESS_201369] Discontinuation of Study Device 894 
In the case of an unanticipated system malfunction resulting in a severe hypoglycemia or DKA event (or  a [ADDRESS_201370] led to severe hypoglyce mia or DKA), use of the SteadiSet will be suspended  [ADDRESS_201371] will be discontinued if any of the 900 
following occur: 901 
ï‚§ The investigator believes it is unsafe for the subj ect to continue on the intervention. This 902 
could be due to the development of a new medical co ndition or worsening of an existing 903 
condition; or subject behavior contrary to the indi cations for use of the device that imposes [ADDRESS_201372]â€™s safety 905 
ï‚§ The subject requests that the treatment be stopped 906 
ï‚§ Subject pregnancy 907 
ï‚§ Two distinct epi[INVESTIGATOR_171665] 6.2.4 908 
ï‚§ Two distinct severe hypoglycemia events as defined in Section 6.2.3 909 
ï‚§ One epi[INVESTIGATOR_171666] 6.2.[ADDRESS_201373] to continue to use the SteadiSet, use will be 917 
discontinued. 918  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 45 OF 59 6.6.2  Criteria for Suspending or Stoppi[INVESTIGATOR_3396] 919 
In addition to the suspension of device use due to a UADE as described in Section 6.6.1, study activit ies 920 
could be similarly suspended if the manufacturer of  any constituent study device requires stoppage of 921 
device use for safety reasons (e.g., product recall ). The affected study activities may resume if the 922 
underlying problem can be corrected by a protocol o r system modification that will not invalidate the 923 
results obtained prior to suspension. 924  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 46 OF 59 Chapter 7:  Miscellaneous Considerations 925 
7.1 Drugs Used as Part of the Protocol 926 
Subjects will use their personal insulin, either in sulin lispro (Humalog) or insulin aspart (NovoLog),  [ADDRESS_201374]â€™s insulin changes from Humal og to NovoLog, or vice versa, it will be noted in t he 929 
case report form and analysed accordingly. 930 
7.2 Collection of Medical Conditions and Medications 931 
Pre-Existing Condition : Any medical condition that is either present at s creening, a chronic disease, or a [ADDRESS_201375]â€™s hea lth during the course of the study (e.g., prior 933 
myocardial infarction or stroke). 934 
Medical Conditions during the study : In addition to conditions meeting the reporting r equirements for an 935 
adverse event or device issue as described above, t he following medical conditions should also be 936 
reported: (1) new diagnosis of a chronic disease (i .e., not present at the time of enrollment), and (2 ) any [ADDRESS_201376]â€™s a bility to carry out any aspect of the protocol or c ould [ADDRESS_201377] an outcome assessment. New conditions or wor sening of a previous medical condition should be 939 
reported as adverse events. 940 
Medications : All medications for the treatment of pre-existing  conditions at screening and/or adverse [ADDRESS_201378] be removed bef ore magnetic resonance imaging (MRI), 946 
computed tomography (CT) or diathermy treatment. Su bjects may continue in the trial after temporarily [ADDRESS_201379]â€™s preference. [ADDRESS_201380] will be discontinu ed from the study. The occurrence of pregnancy will  be 953 
reported to the Coordinating Center within seven da ys and to the JCHR IRB on the Unanticipated 954 
Problem form within seven (7) calendar days. [ADDRESS_201381] may withdraw at any time. For subjects who 959 
withdraw, their data will be used up until the time  of withdrawal. 960  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-[ADDRESS_201382] information may also b e 964 
provided to research sites involved in the study. 965  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 48 OF 59 Chapter 8:  Statistical Considerations 966 
8.1 Statistical and Analytical Plans 967 
The approach to sample size and statistical analyse s is summarized below.  968 
8.2 Statistical Hypotheses 969 
A 95% confidence interval (95% CI) for the 7-day su rvival rate (i.e., primary efficacy endpoint as def ined 970 
in Section 8.4.2 below) will be calculated.  971 
The null/alternative hypotheses are: 972 
a. Null Hypothesis : The success rate is 75%.  973 
b. Alternative Hypothesis : The success rate is different from 75% (two-sided ). 974 
8.3 Power 975 
Assuming (1) n=120 subjects completing the study fo r each insulin type, (2) a null hypothesis stating that 976 
the success rate is 75%, (3) a true success rate of  83%, (4) [ADDRESS_201383] (5) within-su bject [ADDRESS_201384] 0.4, and (6) two-sided type 1 error rate of 5% we will have statistical power o f 87%. [ADDRESS_201385] 86% power.  979 
8.4 Outcome Measures 980 
8.4.1  Clinical Events Committee 981 
Clinical Primary and Secondary Endpoint events will  be adjudicated by [CONTACT_34164] 982 
(CEC). The CEC will be made up of the Medical Monit or, Lead Investigator and one independent [ADDRESS_201386] occurred during the study as outlin ed 986 
in the CEC Charter. Operational details will be def ined in a separate Clinical Events Committee SOP 987 
document. 988 
8.4.2  Primary Efficacy Endpoint 989 
Percentage of successfully-inserted SteadiSet infus ion sets (i.e., not removed within 8 hours of inser tion) 990 
that are not withdrawn from use prior to 7 days (16 8 hours) due to either (1), (2), or (3): 991 
1. Blood Glucose value â‰¥250 mg/dL with ketones >1.0 mm ol/L, in the absence of illness or other 992 
physiological stress.  993 
2. Blood Glucose value â‰¥250 mg/dL for at least [ADDRESS_201387] 50 mg/dL. In the a bsence of BGM testing immediately prior to or [ADDRESS_201388]â€™s safety. 998  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 49 OF 59 8.4.3  Safety Endpoints 999 
The incidence, severity, and relationship to the in vestigational device of all reported adverse events  1000 
(serious and non-serious including DKA and severe h ypoglycemia) from day of insertion through day of 1001 
device removal for each wear period. 1002 
8.4.4  Key Secondary Endpoint 1003 
Proportion (%) of SteadiSet infusion sets withdrawn  from use at any time following insertion prior to 7 1004 
days (168 hours) as evidenced by [CONTACT_171681]. NOTE: infusion set  1005 
removals prior to 168 hours due to miscalculation o f date and/or time, along with other removals that 1006 
cannot be ascribed to the investigational device pe rformance, are excluded from this proportion 1007 
calculation. 1008 
1. Infusion set failure as defined in the Primary Endp oint (including any such removals occurring [ADDRESS_201389] 8 hours following set insertion) 1010 
2. Evidence of infusion set site infection defined as requiring treatment or at the investigatorâ€™s 1011 
judgment  1012 
3. Cannula dislodgement from subcutaneous (SC) space ( with or without liquid leakage at the 1013 
cannula insertion site) [ADDRESS_201390] 1016 
b. Accidental removal events (e.g., tubing caught on d oorknob) are excluded from this 1017 
proportion calculation 1018 
4. Occurrence of a non-resolvable pump occlusion alarm ,  1019 
5. Other device malfunction (e.g., inability to pi[INVESTIGATOR_171645], bending, or other malformation that might [ADDRESS_201391] insulin infusion, securement failure) [ADDRESS_201392] tolerability levels for the infusion set in sertion as assessed by a pain scale of 0 to 100 wit h 1030 
zero being no pain and 100 being significant pain 1031 
4. Hyperglycemia trends in days 1-3 versus after day 3  1032 
5. Infusion set performance (including set failures as  defined above and also glucose metrics, insulin 1033 
doses, pump occlusion alarms and hyperglycemia tren ds) in subjects who use low doses (e.g., 1034 
<25 units/day) of insulin and in subjects who exper ience frequent stops and start of pump use 1035 
8.4.6  Exploratory Endpoint 1036 
1. HbA1c change from baseline to the end of study part icipation. 1037  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 50 OF 59 8.5 Analysis Datasets and Sensitivity Analyses 1038 
1. Only wears of the investigational infusion set will  be included in the analysis (i.e., any wear of a 1039 
personal infusion set will be excluded) [ADDRESS_201393] six wear 1042 
periods will be considered as â€œcompleters.â€  1043 
3. Since this is not a randomized trial, the intention -to-treat principle does not apply. 1044 
4. All reported adverse events will be included in the  safety analyses. 1045 
8.6 Analysis of the Primary Efficacy Endpoint(s) 1046 
Analysis will be done separately for each insulin t ype (Humalog and Novolog). [ADDRESS_201394] 7 days. Any infusion sets t hat are removed prior to day 7 without meeting the stated 1049 
failure criteria will be treated as a censored obse rvation. 1050 
A two-sided 95% confidence interval (95% CI) for th e 7-day survival rate will be calculated with a [ADDRESS_201395] wear multiple infusion sets. A 1052 
corresponding p-value will be given for the null hy pothesis that the true survival probability is 75%.  1053 
8.7 Analysis of the Secondary and Exploratory Endpoints  1054 
If results from the primary analysis are comparable  for Humalog and Novolog, then the data will be 1055 
pooled for secondary analyses. Otherwise, separate analyses will be done by [CONTACT_171694]. Percentage o f 1056 
SteadiSet infusion sets not withdrawn from use prio r to 7 days (168 hours) as evidenced by [CONTACT_171695] [ADDRESS_201396] will be used to compare the central  lab HbA1c values measured at the final study visit  1060 
versus the Day 0 value. A two-sided 95% CI will be given for the mean difference. Only subjects with a  [ADDRESS_201397] comparisons will be 1062 
done with selected CGM metrics. These will include data from the final 14 days of the study compared 1063 
with the baseline CGM data. 1064 
Survey and pain assessment results will be tabulate d. 1065 
The other continuous and binary outcomes will be su mmarized as appropriate to their distributions (i.e ., 1066 
mean (SD), median (IQR), or n (%)). Plots and 95% C I will be calculated for selected outcomes. 1067 
CGM metrics will be calculated over the entire stud y period (24-hour, daytime, and nighttime) and by 1068 
study week (24 hour only). 1069 
Hyperglycemia Trend in Days 1-3 versus after Day 3 1070 
The trend in hyperglycemia in days 1-3 versus after  day 3 will be assessed with the CGM metrics % time  1071 
above 180 mg/dL, % time above 250 mg/dL, and mean g lucose. Summary statistics appropriate to their 1072 
distributions, boxplots will be used to compare dat a in days 1-3 versus after day 3. Formal comparison s 1073 
will be done using paired t-tests (or non-parametri c analogs if the data are not approximately normall y 1074 
distributed) to account for the correlated data fro m the same subject. 1075  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 51 OF 59 8.8 Safety Analyses 1076 
All enrolled subjects will be included in these ana lyses and all their safety events up to the end of study 1077 
will be listed. In particular, any AEs involving hy perglycemia/ketosis will include an assessment whet her [ADDRESS_201398] atistics appropriate to the distribution of each 1083 
variable. Will include: 1084 
ï‚§ Age 1085 
ï‚§ Gender 1086 
ï‚§ Race/ethnicity 1087 
ï‚§ Diabetes duration 1088 
ï‚§ HbA1c 1089 
ï‚§ BMI 1090 
ï‚§ CGM metrics (including estimated HbA1c) 1091 
ï‚§ Insulin type 1092 
ï‚§ Infusion set type 1093 
8.10 Planned Interim Analyses 1094 
No formal interim efficacy analyses are planned for  this study. 1095 
8.11 Multiple Comparison/Multiplicity 1096 
Since this is an exploratory and a single arm trial , there will be no formal adjustment for multiple 1097 
comparisons. 1098  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 52 OF 59 Chapter 9:  Data Collection and Monitoring 1099 
9.1 Case Report Forms and Other Data Collection 1100 
The main study data are collected on electronic cas e report forms (eCRFs). When data are directly 1101 
collected in electronic case report forms, this wil l be considered the source data. For any data point s for 1102 
which the eCRF is not considered source (e.g., lab results that are transcribed from a printed report into 1103 
the eCRF), the original source documentation must b e maintained in the subjectâ€™s study chart or medica l [ADDRESS_201399] be 1106 
recorded (e.g., office note, visit record, etc.). [ADDRESS_201400]. These documents sho uld be retained for a longer period, however, if 1116 
required by [CONTACT_427]. No records will be d estroyed without the written consent of the sponsor , if 1117 
applicable. It is the responsibility of the sponsor  to inform the investigator when these documents no  1118 
longer need to be retained. 1119 
9.3 Quality Assurance and Monitoring 1120 
Designated personnel from the Coordinating Center w ill be responsible for maintaining quality assuranc e 1121 
(QA) and quality control (QC) systems to ensure tha t the clinical portion of the trial is conducted an d data 1122 
are generated, documented and reported in complianc e with the protocol, Good Clinical Practice (GCP) 1123 
and the applicable regulatory requirements, as well  as to ensure that the rights and wellbeing of tria l 1124 
subjects are protected and that the reported trial data are accurate, complete, and verifiable. Advers e 1125 
events will be prioritized for monitoring. 1126 
A risk-based monitoring (RBM) plan will be develope d and revised as needed during the study, consisten t 1127 
with the FDA â€œGuidance for Industry Oversight of Cl inical Investigations â€” A Risk-Based Approach to 1128 
Monitoringâ€ (August 2013). Study conduct and monito ring will conform with 21 Code of Federal 1129 
Regulations (CFR) 812. This plan describes in detai l who will conduct the monitoring, at what frequenc y [ADDRESS_201401] eligibility and adverse events, pri mary 1133 
and secondary endpoints. Therefore, the RBM plan wi ll focus on these areas. As much as possible, remot e 1134 
monitoring will be performed in real-time with on-s ite monitoring performed to evaluate the verity and  1135 
completeness of the key site data. Elements of the RBM may include: [ADDRESS_201402] (IRB) cover age and informed consent procedures 1138 
Central (remote) data monitoring: validation of dat a entry, data edits/audit trail, protocol review of  1139 
entered data and edits, statistical monitoring, stu dy closeout 1140  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 53 OF 59 On-site monitoring (site visits): source data verif ication, site visit report 1141 
Agent/Device accountability [ADDRESS_201403] access to all trial related sit es, source data/documents, and reports for the purp ose of [ADDRESS_201404], the investigator, or the stu dy 1156 
site staff. A significant (or major) deviation is a ny deviation that departs from the established mate rials in [ADDRESS_201405] that it poses an increase in the risk to  subjects, adversely affects the welfare, rights, o r safety 1158 
of the research subjects, or negatively influences the scientific study integrity. As a result of a si gnificant 1159 
deviation, a corrective and preventive action plan shall be developed by [CONTACT_171696] 1160 
promptly. 1161 
The site PI/study staff is responsible for knowing and adhering to their IRB requirements. Further det ails 1162 
about the handling of protocol deviations will be i ncluded in the monitoring plan. 1163  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 54 OF 59 Chapter 10:  Ethics/Protection of Human Subjects [ADDRESS_201406] 1165 
The investigator will ensure that this study is con ducted in full conformity with Regulations for the 1166 
Protection of Human Subjects of Research codified i n 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 1167 
and/or the ICH E6. 1168 
10.2 Institutional Review Boards 1169 
The protocol, informed consent form(s), recruitment  materials, and all subject materials will be submi tted [ADDRESS_201407] is enrolled. Any amendment to th e protocol will require review and approval by [CONTACT_941] 1172 
IRB before the changes are implemented to the study . All changes to the consent form will be IRB 1173 
approved; a determination will be made regarding wh ether previously consented subjects need to be re- 1174 
consented. 1175 
10.3 Informed Consent Process 1176 
10.3.1  Consent Procedures and Documentation 1177 
Informed consent is a process that is initiated pri or to the individualâ€™s agreeing to participate in t he study 1178 
and continues throughout the individualâ€™s study par ticipation. Extensive discussion of risks and possi ble [ADDRESS_201408] b y the participating investigators, their staff, and  the 1193 
sponsor(s) and their agents. This confidentiality i s extended to cover testing of biological samples a nd [ADDRESS_201409] all documents and records required to be 1200 
maintained by [CONTACT_093], including but not l imited to, medical records (office, clinic, or hosp ital) 1201 
and pharmacy records for the subjects in this study . The clinical study site will permit access to suc h 1202 
records. 1203  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-[ADDRESS_201410]â€™s contact [CONTACT_171697] [ADDRESS_201411]â€™s contact  [INVESTIGATOR_1660] [ADDRESS_201412] can be included  1219 
in the study. Biological samples will be destroyed/ discarded after laboratory analysis.  1220 
When the study is completed, access to study data a nd/or samples will be provided through 1221 
Capi[INVESTIGATOR_171642]. 1222  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 56 OF 59 Chapter 11:  References [ADDRESS_201413], T. & PfÃ¼tzner, A. Pi[INVESTIGATOR_171667] 1224 
of Optimal Frequency for Changing Catheters in Insu lin Pump Therapyâ€”Trouble Starts on 1225 
Day 3. J. Diabetes Sci. Technol.  4, 976â€“982 (2010). [ADDRESS_201414] of Age of Infusion Site and Type of Rapid-A cting Analog on 1227 
Pharmacodynamic Parameters of Insulin Boluses in Yo uth With Type 1 Diabetes Receiving 1228 
Insulin Pump Therapy. Diabetes Care  32, 240â€“244 (2009). 1229 
3. Patel, P. J. et al.  Randomized trial of infusion set function: steel v ersus teflon. Diabetes 1230 
Technol. Ther.  16, 15â€“19 (2014). [ADDRESS_201415], E., Guerci, B., Leguerrier, A.-M., Boizel, R., & Accu-Chek FlexLink Study Group. 1232 
Lower rate of initial failures and reduced occurren ce of adverse events with a new catheter 1233 
model for continuous subcutaneous insulin infusion:  prospective, two-period, observational, 1234 
multicenter study. Diabetes Technol. Ther.  12, 769â€“773 (2010). 1235 
5. Clausen, T. S., Kaastrup, P. & Stallknecht, B. Effe ct of insulin catheter wear-time on 1236 
subcutaneous adipose tissue blood flow and insulin absorption in humans. Diabetes Technol. 1237 
Ther.  11, 575â€“580 (2009). 1238 
6. Heinemann, L. Variability of insulin absorption and  insulin action. Diabetes Technol. Ther.  1239 
4, 673â€“682 (2002). 1240 
7. PfÃ¼tzner, A. et al.  Using Insulin Infusion Sets in CSII for Longer Tha n the Recommended 1241 
Usage Time Leads to a High Risk for Adverse Events:  Results From a Prospective 1242 
Randomized Crossover Study. J. Diabetes Sci. Technol.  (2015) 1243 
doi:10.1177/1932296815604438. 1244 
8. Waldenmaier, D. et al.  A prospective study of insulin infusion set use fo r up to 7 days: early [ADDRESS_201416] on glycemic control.  Diabetes Technol. Ther.  (2020) 1246 
doi:10.1089/dia.2019.0445. 1247 
9. Lal, R. A. et al.  Longevity of the novel ConvaTec infusion set with Lantern technology. 1248 
Diabetes Obes. Metab.  (2021) doi:10.1111/dom.[ZIP_CODE]. [ADDRESS_201417], E. Insulin delivery route for the artificia l pancreas: subcutaneous, intraperitoneal, or 1250 
intravenous? Pros and cons. J. Diabetes Sci. Technol.  2, 735â€“738 (2008). 1251 
11. Hajnsek, M. et al.  The single-port concept: combining optical glucose  measurement with 1252 
insulin infusion. Acta Diabetol.  51, 883â€“886 (2014). [ADDRESS_201418] application of a transcutaneous optical sing le-port glucose 1254 
monitoring device in patients with type 1 diabetes mellitus. Biosens. Bioelectron.  (2016) 1255 
doi:10.1016/j.bios.2016.08.039. 1256 
13. Tschaikner, M. et al.  Novel Single-Site Device for Conjoined Glucose Sen sing and Insulin 1257 
Infusion: Performance Evaluation in Diabetes Patien ts During Home-Use. IEEE Trans. 1258 
Biomed. Eng.  67, 323â€“332 (2020). 1259  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 57 OF 59 14. Eisler, G. et al.  In vivo investigation of the tissue response to co mmercial Teflon insulin 1260 
infusion sets in large swine for 14 days: the effec t of angle of insertion on tissue histology 1261 
and insulin spread within the subcutaneous tissue. BMJ Open Diabetes Res. Amp Care  7, 1262 
e000881 (2019). 1263 
15. Liebner, T. et al.  Insulinpumpenkatheter â€“ Komplikationen im Kindes- und Jugendalter. 1264 
Diabetol. Stoffwechs.  5, P151 (2010). 1265 
16. PfÃ¼tzner, A. et al.  Using Insulin Infusion Sets in CSII for Longer Tha n the Recommended 1266 
Usage Time Leads to a High Risk for Adverse Events:  Results From a Prospective 1267 
Randomized Crossover Study. J. Diabetes Sci. Technol.  9, 1292â€“8 (2015). [ADDRESS_201419], E., Guerci, B., Leguerrier, A.-M. & Boizel,  R. Lower rate of initial failures and 1269 
reduced occurrence of adverse events with a new cat heter model for continuous subcutaneous 1270 
insulin infusion: prospective, two-period, observat ional, multicenter study. Diabetes Technol. 1271 
Ther.  12, 769â€“773 (2010). 1272 
18. van Bon, A. C., Bode, B. W., Sert-Langeron, C., DeV ries, J. H. & Charpentier, G. Insulin 1273 
Glulisine Compared to Insulin Aspart and to Insulin  Lispro Administered by [CONTACT_171698] 1274 
Subcutaneous Insulin Infusion in Patients with Type  1 Diabetes: A Randomized Controlled 1275 
Trial. Diabetes Technol. Ther.  13, 607â€“614 (2011). 1276 
19. Clausen, T. S., Kaastrup, P. & Stallknecht, B. Effe ct of insulin catheter wear-time on 1277 
subcutaneous adipose tissue blood flow and insulin absorption in humans. Diabetes Technol. 1278 
Ther.  11, 575â€“580 (2009). [ADDRESS_201420] of Age of Infusion Site and Type of Rapid-A cting Analog on 1280 
Pharmacodynamic Parameters of Insulin Boluses in Yo uth With Type 1 Diabetes Receiving 1281 
Insulin Pump Therapy. Diabetes Care  32, 240â€“244 (2009). 1282 
21. Vaughn, D. E. & Muchmore, D. B. Use of recombinant human hyaluronidase to accelerate 1283 
rapid insulin analogue absorption: experience with subcutaneous injection and continuous [ADDRESS_201421]. Off. J. Am. Coll. Endocrinol. Am. As soc. Clin. Endocrinol.  17, 914â€“ 1285 
21. 1286 
22. Luijf, Y. M. et al.  Patch pump versus conventional pump: postprandial glycemic excursions 1287 
and the influence of wear time. Diabetes Technol. Ther.  15, 575â€“9 (2013). 1288 
23. Simic, A. et al.  Survival assessment of the extended-wear insulin i nfusion set featuring 1289 
lantern technology in adults with type 1 diabetes b y the glucose clamp technique. Diabetes 1290 
Obes. Metab.  23, 1402â€“1408 (2021). 1291 
24. Patel, P. J. et al.  Randomized Trial of Infusion Set Function: Steel V ersus Teflon. Diabetes 1292 
Technol. Ther.  16, 1â€“5 (2013).  1293  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 58 OF 59 Appendix A:  Relevant Literature on Infusion Sets 1294 
A.1 Failure Modes and Failure Rates for Current Infusio n Sets 1295 
The nationwide pediatric surveillance of insulin in fusion sets in [LOCATION_013] and Austria reported that 19 2 1296 
(29%) patients had no infusion set issues at all. H owever, the other 475 (71%) patients reported 1,[ADDRESS_201422] often reported device adverse even t was cannula obstruction (32.9%). A total of 14.2%  1298 
of the patients reported that they had blood in the  insulin infusion cannula; 11.1% had skin with redn ess 1299 
and 10.1% reported cannula kinking. 36.2% of the re ported complications occurred by [CONTACT_4475] 1 of infusion 1300 
set usage and 82.4% by [CONTACT_171699] 2.15 1301 
PfÃ¼tzner et al. performed a prospective randomized controlled cro ssover clinical trial to investigate the 1302 
tolerability of 2-day use of commercial insulin inf usion sets in comparison to 4-day use in a real-wor ld 1303 
setting. Twenty-four patients with T1D managed with  an insulin pump were studied during two 3-month 1304 
periods. The number of cannula-related adverse even ts was 290 with 2-day use versus 495 with 4-day use  1305 
(P < .05). The overall number of treatment related events was 750 with 2-day use versus 934 with 4-day  1306 
use (P < .001). There was no difference in glycemic  control between the treatment arms. Treatment 1307 
satisfaction was higher with 2-day use (very high/h igh satisfaction: 90.4% versus 4 day-use: 77.3%, P < 1308 
.05). The authors concluded that using an infusion set for a longer than 2-[ADDRESS_201423] et al.  performed a prospective, two-period, observational , multicenter study in 45 T1D 1311 
outpatients. During the initial 1-month period the patients used a Teflon cannula (98% of cases) 1312 
and crossed over to an investigational insulin infu sion set (Accu-Chek FlexLink, Disetronic Medical 1313 
Systems AG) for a 3-month period. Forty-five initia l infusion failures occurred in 14 patients among 1314 
507 commercial Teflon cannula insertions (8.9% of c ases), whereas 15 failures were seen in nine 1315 
patients during 488 investigational cannula inserti ons (3.1% of cases) (P<0.001). The overall rate of late 1316 
cumulative events was 113 of 507 (22%) with the com mercial infusion set versus 66 of 488 (14%) using 1317 
the investigational infusion set (P<0.001). The occ urrence of pain, skin reaction, or redness at the i nfusion 1318 
site was lower using the investigational insulin in fusion cannula.17 1319 
Van Bon et al.  conducted a multi-center trial of 256 patients on three insulins. Approximately 30% of [ADDRESS_201424] 1 perceived set failu re during the 13-week study period with each insuli n. 1321 
More than 60% of patients experienced unexpected hy perglycemia during the 13-week study period. 1322 
These results are similar to expertsâ€™ experience ma naging T1D using an insulin pump and currently [ADDRESS_201425] common reason for 1327 
infusion set removal was adhesive failure (50%), fo llowed by [CONTACT_171700] a correctio n 1328 
bolus (33%), hyperglycemia with elevated ketones (8 %), and infection of the insertion site (8%).[ADDRESS_201426] of Wear Time on PK/PD and Test Meal Response  [ADDRESS_201427] challenge and sh owed substantial declines in glucose response 1334 
between day 1 and day 3 of catheter wear.22 This improved glucose response was seen for both p atch 1335 
(tubeless) and conventional insulin pump systems, w hich was presumably a result of improved early [ADDRESS_201428] 3 or so  days of catheter wear time.  1337  
	
			
JAEB CENTER FOR HEALTH RESEARCH  
CAPI[INVESTIGATOR_171638]  150-1261-00  CB1  PROTOCOL V 5.0 CONFIDENTIAL P AGE 59 OF 59 Simic et al.  performed a clamp study with 16 subjects assessing  a new extended-wear infusion set with an 1338 
anti-inflammatory coating and Lantern technology (C onvaTec) and found that while insulin absorption 1339 
decreased over wear time, it was also significantly  faster 4 and 7 days after insertion. None of the p atients 1340 
experienced severe hypoglycemia over a period of 7 days. The authors claim that increased rate of 1341 
absorption my facilitate better postprandial contro l.23 1342 
A.3 Experience with Extended Wear (>3 days) 1343 
Patel et al. performed a randomized crossover clinical trial to compare the performance of Teflon versus 1344 
stainless steel insulin infusion sets in ambulatory  humans for up to 1 week. The subjects used a Quick -Set 1345 
or a Sure-T CSII cannula until the infusion set fai led or was worn for 1 week. After 7 days, both type s of 1346 
infusion sets had a 64% failure rate. Eighty-seven percent of the steel sets and 77% of the Teflon set s 1347 
were functioning after 3 days (this number includes  the 15% that failed on the first day because of 1348 
kinking), after 5 days 68% of the steel and 59% of the Teflon sets were functioning, after 6 days 53% of 1349 
the steel and 46% of the Teflon sets were functioni ng, and at the end of 7 days 32% of the steel and 3 2% 1350 
of the Teflon sets were functioning. Overall, 30% f ailed because of hyperglycemia and a failed correct ion 1351 
dose, 13% were removed for pain, 10% were pulled ou t by [CONTACT_21317], 10% had erythema and/or induration 1352 
of >10 mm, 5% fell out because of loss of adhesion,  and 4% were removed for infection. The main [ADDRESS_201429]. There was no increase in hyperglycemia or dail y 1354 
insulin requirements when an infusion set was succe ssfully used for 7 days.24 1355 
Waldenmaier et al. tested extended wear (â‰¥7 days) o f commercial steel and Teflon insulin infusion sets  in 1356 
40 adult subjects on insulin pump therapy. 66% of 1 60 inserted infusion sets were used for 7 days with  no 1357 
obvious difference between steel and Teflon infusio n sets (mean wear time was 6.2 days). The main 1358 
reasons for early infusion set replacements were oc clusions (19%), adhesive issues (4%), and accidenta l 1359 
removal (4%). Comparing glycemic control during day  1-3 and 1-7, there was no difference in mean BG 1360 
and insulin dose. The authors concluded that infusi on set replacement intervals may be individualized 1361 
beyond the currently labeled maximum use duration.8 1362 
Lal et al.  assessed longevity of the previously mentioned Con vaTec infusion set in a pi[INVESTIGATOR_171668] 1363 
22 subjects. 45% of the novel infusion sets lasted 10 days, with a median wear time of 9.1 days. While  the 1364 
mean BG concentration increased significantly over time, the total daily insulin dose did not change 1365 
throughout 10 days of set wear.9 1366 
Recently, Medtronic reported an overall wear period  success rate of 74.8% at 7 days using an extended 1367 
wear infusion set (Buckingham et al., poster, Ameri can Diabetes Association annual meeting, 2021), 1368 
leading to device approval by [CONTACT_1622] (510k). There  has been no marketing experience reported for [ADDRESS_201430] limited life span, and room for improvement is  present. 1372  
	
			